2024/02/06 更新

写真a

アラカワ リョウスケ
荒川 亮介
Arakawa Ryosuke
所属
大学院医学研究科 薬理学分野 大学院教授
医学部 薬理学 大学院教授
職名
大学院教授
外部リンク

研究キーワード

  • 精神医学

  • 薬理学

研究分野

  • ライフサイエンス / 薬理学

  • ライフサイエンス / 精神神経科学

学歴

  • 日本医科大学大学院精神・行動医学分野

    2004年4月 - 2008年3月

      詳細を見る

  • 日本医科大学医学部

    1993年4月 - 1999年3月

      詳細を見る

経歴

  • 日本医科大学   薬理学教室   教授

    2021年4月

      詳細を見る

  • 日本医科大学   精神医学教室   准教授

    2019年10月 - 2021年3月

      詳細を見る

  • Karolinska Institutet   Department of Clinical Neuroscience   Assistant Professor

    2014年4月 - 2019年9月

      詳細を見る

  • 国立精神・神経医療研究センター   精神保健研究所成人精神保健研究部   認知機能研究室長

    2012年7月 - 2014年3月

      詳細を見る

  • 厚生労働省   社会・援護局障害保健福祉部精神・障害保健課   心の健康づくり対策官

    2010年4月 - 2012年6月

      詳細を見る

  • 放射線医学総合研究所   分子イメージング研究センター   博士研究員

    2008年4月 - 2010年3月

      詳細を見る

  • 日本医科大学   精神医学教室   医員

    1999年5月 - 2004年3月

      詳細を見る

▼全件表示

論文

  • Synthesis of [11C]BIIB104, an α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic-Acid-Positive Allosteric Modulator, and Evaluation of the Bio-Distribution in Non-Human Primate Brains Using Positron Emission Tomography. 国際誌

    Sangram Nag, Kevin Jia, Ryosuke Arakawa, Prodip Datta, Daniel Scott, Christopher Shaffer, Mohammad Mahdi Moein, Matthew Hutchison, Maciej Kaliszczak, Christer Halldin

    Molecules (Basel, Switzerland)   29 ( 2 )   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this study was to measure the brain penetrance and kinetics of BIIB104, a first-in-class AMPA receptor potentiator developed for cognitive impairment associated with schizophrenia. It was recently halted in phase 2 clinical development, and there are a lack of tools to directly measure AMPA receptor engagement. To achieve this, the drug candidate was radiolabeled with carbon-11, and its brain penetrance and kinetics were measured in non-human primates via dynamic PET scans. Radiolabeling was achieved through a three-step nucleophilic [11C]cyanation reaction in one pot, resulting in the high radioactivity and radiochemical purity (>99%) of [11C]BIIB104. The study found that [11C]BIIB104 entered the non-human primate brains at 4-5% ID at peak, with a homogeneous distribution. However, a mild regional heterogeneity was observed in the thalamus. The lack of conclusive evidence for a change in regional values after BIIB104 dosing suggests that any specific binding component of BIIB104 is negligible compared to the free and non-specific components in the living brain. Overall, the study demonstrated high brain uptake with minor variability in [11C]BIIB104 distribution across various brain regions, its kinetics were consistent with those of passive diffusion, and the dominating components were the free concentration and non-specific binding. This information is valuable for understanding the potential effects and mechanisms of BIIB104 in the brain.

    DOI: 10.3390/molecules29020427

    PubMed

    researchmap

  • Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [18F]FE-PE2I-OH for Translational Dopamine Transporter Imaging. 国際誌

    Magnus Schou, Nahid Amini, Akihiro Takano, Ryosuke Arakawa, Kenneth Dahl, Miklos Toth, Marie Svedberg, Andrea Varrone, Christer Halldin

    ACS chemical neuroscience   14 ( 20 )   3732 - 3736   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Undesired radiometabolites can be detrimental to the development of positron emission tomography (PET) radioligands. Methods for quantifying radioligand metabolites in brain tissue include ex vivo studies in small animals or labeling and imaging of the radiometabolite(s) of interest. The latter is a time- and resource-demanding process, which often includes multistep organic synthesis. We hypothesized that this process could be replaced by making use of liver microsomes, an in vitro system that mimics metabolism. In this study, rat liver microsomes were used to prepare radiometabolites of the dopamine transporter radioligand [18F]FE-PE2I for in vitro imaging using autoradiography and in vivo imaging using PET in rats and nonhuman primates. The primary investigated hydroxy-metabolite [18F]FE-PE2I-OH ([18F]2) was obtained in a 2% radiochemical yield and >99% radiochemical purity. In vitro and in vivo imaging demonstrated that [18F]2 readily crossed the blood-brain barrier and bound specifically and reversibly to the dopamine transporter. In conclusions, the current study demonstrates the potential of liver microsomes in the production of radiometabolites for translational imaging studies and radioligand discovery.

    DOI: 10.1021/acschemneuro.3c00458

    PubMed

    researchmap

  • Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain. 国際誌

    Brendon E Cook, Sangram Nag, Ryosuke Arakawa, Edward Yin-Shiang Lin, Nancy Stratman, Kevin Guckian, Heike Hering, Mukesh Lulla, Jinkuk Choi, Cristian Salinas, Nathan E Genung, Anton Forsberg Morén, Martin Bolin, Giulia Boscutti, Christophe Plisson, Laurent Martarello, Christer Halldin, Maciej A Kaliszczak

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    O-GlcNAcylation is thought to play a role in the development of tau pathology in Alzheimer's disease because of its ability to modulate tau's aggregation propensity. O-GlcNAcylation is regulated by 2 enzymes: O-GlcNAc transferase and O-GlcNAcase (OGA). Development of a PET tracer would therefore be an essential tool for developing therapeutic small-molecule inhibitors of OGA, enabling clinical testing of target engagement and dose selection. Methods: A collection of small-molecule compounds was screened for inhibitory activity and high-affinity binding to OGA, as well as favorable PET tracer attributes (multidrug resistance protein 1 efflux, central nervous system PET multiparameter optimization, etc.). Two lead compounds with high affinity and selectivity for OGA were selected for further profiling, including OGA binding to tissue homogenate using a radioligand competition binding assay. In vivo pharmacokinetics were established using a microdosing approach with unlabeled compounds in rats. In vivo imaging studies were performed in rodents and nonhuman primates (NHPs) with 11C-labeled compounds. Results: Two selected candidates, BIO-735 and BIO-578, displayed promising attributes in vitro. After radiolabeling with tritium, [3H]BIO-735 and [3H]BIO-578 binding in rodent brain homogenates demonstrated dissociation constants of 0.6 and 2.3 nM, respectively. Binding was inhibited, concentration-dependently, by homologous compounds and thiamet G, a well-characterized and structurally diverse OGA inhibitor. Imaging studies in rats and NHPs showed both tracers had high uptake in the brain and inhibition of binding to OGA in the presence of a nonradioactive compound. However, only BIO-578 demonstrated reversible binding kinetics within the time frame of a PET study with a 11C-labeled molecule to enable quantification using kinetic modeling. Specificity of tracer uptake was confirmed with a 10 mg/kg blocking dose of thiamet G. Conclusion: We describe the development and testing of 2 11C PET tracers targeting the protein OGA. The lead compound BIO-578 demonstrated high affinity and selectivity for OGA in rodent and human postmortem brain tissue, leading to its further testing in NHPs. NHP PET imaging studies showed that the tracer had excellent brain kinetics, with full inhibition of specific binding by thiamet G. These results suggest that the tracer [11C]BIO-578 is well suited for further characterization in humans.

    DOI: 10.2967/jnumed.122.265225

    PubMed

    researchmap

  • Development of a Novel [11C]CO-Labeled Positron Emission Tomography Radioligand [11C]BIO-1819578 for the Detection of O-GlcNAcase Enzyme Activity. 国際誌

    Sangram Nag, Martin Bolin, Prodip Datta, Ryosuke Arakawa, Anton Forsberg Morén, Yasir Khani Maynaq, Edward Lin, Nathan Genung, Heike Hering, Kevin Guckian, Laurent Martarello, Maciej Kaliszczak, Christer Halldin

    ACS chemical neuroscience   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Imaging O-GlcNAcase OGA by positron emission tomography (PET) could provide information on the pathophysiological pathway of neurodegenerative diseases and important information on drug-target engagement and be helpful in dose selection of therapeutic drugs. Our aim was to develop an efficient synthetic method for labeling BIO-1819578 with carbon-11 using 11CO for evaluation of its potential to measure levels of OGA enzyme in non-human primate (NHP) brain using PET. Radiolabeling was achieved in one-pot via a carbon-11 carbonylation reaction using [11C]CO. The detailed regional brain distribution of [11C]BIO-1819578 binding was evaluated using PET measurements in NHPs. Brain radioactivity was measured for 93 min using a high-resolution PET system, and radiometabolites were measured in monkey plasma using gradient radio HPLC. Radiolabeling of [11C]BIO-1819578 was successfully accomplished, and the product was found to be stable at 1 h after formulation. [11C]BIO-1819578 was characterized in the cynomolgus monkey brain where a high brain uptake was found (7 SUV at 4 min). A pronounced pretreatment effect was found, indicating specific binding to OGA enzyme. Radiolabeling of [11C]BIO-1819578 with [11C]CO was successfully accomplished. [11C]BIO-1819578 binds specifically to OGA enzyme. The results suggest that [11C]BIO-1819578 is a potential radioligand for imaging and for measuring target engagement of OGA in the human brain.

    DOI: 10.1021/acschemneuro.3c00247

    PubMed

    researchmap

  • Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP). 国際誌

    Sangram Nag, Ryosuke Arakawa, Zhisheng Jia, Erik Lachapelle, Lei Zhang, Kevin Maresca, Laigao Chen, Mahabuba Jahan, Timothy Mccarthy, Christer Halldin

    Molecules (Basel, Switzerland)   28 ( 12 )   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Muscarinic acetylcholine receptors (mAChR), including M4, draw attention as therapeutic targets for several neurodegenerative diseases including Alzheimer's disease (AD). PET imaging of M4 positive allosteric modulator (PAM) allows qualification of the distribution as well as the expression of this receptor under physiological conditions and thereby helps to assess the receptor occupancy (RO) of a drug candidate. In this study, our aims were (a) to synthesize a novel M4 PAM PET radioligand [11C]PF06885190 (b) to evaluate the brain distribution of [11C]PF06885190 in nonhuman primates (NHP) and (c) to analyze its radiometabolites in the blood plasma of NHP. Radiolabeling of [11C]PF06885190 was accomplished via N-methylation of the precursor. Six PET measurements were performed using two male cynomolgus monkeys, where three PET measurements were at baseline, two after pretreatment with a selective M4 PAM compound CVL-231 and one after pretreatment with donepezil. The total volume of distribution (VT) of [11C]PF06885190 was examined using Logan graphical analysis with arterial input function. Radiometabolites were analyzed in monkey blood plasma using gradient HPLC system. Radiolabeling of [11C]PF06885190 was successfully accomplished and the radioligand was found to be stable in the formulation, with radiochemical purity exceeding 99% 1 h after the end of the synthesis. [11C]PF06885190 was characterized in the cynomolgus monkey brain where a moderate brain uptake was found at the baseline condition. However, it showed fast wash-out as it dropped to half of the peak at around 10 min. Change of VT from baseline was around -10% after pretreatment with a M4 PAM, CVL-231. Radiometabolite studies showed relatively fast metabolism. Although sufficient brain uptake of [11C]PF06885190 was observed, these data suggest that [11C]PF06885190 might have too low specific binding in the NHP brain to be further applied in PET imaging.

    DOI: 10.3390/molecules28124612

    PubMed

    researchmap

  • First-in-human evaluation of F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.

    Wakabayashi Yuichi, Strenkona Per, Arakawa Ryosuke, Yan Xuefeng, Van Buskirk Maia G, Jenkins Madeline D, Montero Santamaria Jose A, Maresca Kevin P, Takano Akihiro, Liow Jeih-San,Chappie Thomas A, Varrone Andrea, Nag Sangram, Zhang Lei, Hughes Zoë A, Schmidt Christopher J, Doran Shawn D, Mannes Andrew, Zanotti-Fregonara Paolo, Ooms Maarten, Morse Cheryl L, Zoghbi Sami S, Halldin Christer, Pike Victor W, Innis Robert B

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   2022年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.2967/jnumed.122.263838

    researchmap

  • Suicide decline and improved psychiatric treatment status: longitudinal survey of suicides and serious suicide attempters in Tokyo. 国際誌

    Otaka Yasushi, Arakawa Ryosuke, Narishige Ryuichiro, Okubo Yoshiro, Tateno Amane

    BMC psychiatry   22 ( 1 )   221 - 221   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s12888-022-03866-7

    PubMed

    researchmap

  • Target occupancy study and whole-body dosimetry with a MAGL PET ligand [C]PF-06809247 in non-human primates.

    Arakawa Ryosuke, Takano Akihiro, Nag Sangram, Jia Zhisheng, Amini Nahid, Maresca Kevin P, Zhang Lei, Keliher Edmund J, Butler Christopher R, Piro Justin R, Samad Tarek A, Smith Deborah, Nason Deane, O'Neil Steve, Trapa Patrick, Fonseca Kari R, Litchfield John, McCarthy Timothy, Carson Richard E,Halldin Christer

    EJNMMI research   12 ( 1 )   13   2022年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.1186/s13550-022-00882-2

    researchmap

  • Development of C-Labeled ASEM Analogues for the Detection of Neuronal Nicotinic Acetylcholine Receptors (α7-nAChR).

    Nag Sangram,Miranda-Azpiazu Patricia, Jia Zhisheng, Datta Prodip, Arakawa Ryosuke, Moein Mohammad Mahdi, Yang Zhou, Tu Yaoquan, Lemoine Laetitia, Ågren Hans, Nordberg Agneta,Långström Bengt,Halldin Christer

    ACS chemical neuroscience   2022年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1021/acschemneuro.1c00730

    researchmap

  • Factors Regarding Suicide Decline in Japan: A Longitudinal Study on Psychiatric Diagnosis of Serious Suicide Attempters.

    Yasushi Otaka, Ryosuke Arakawa, Ryuichiro Narishige, Yoshiro Okubo, Amane Tateno

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   89 ( 4 )   392 - 398   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The number of suicides in Japan decreased during the period from 2012 through 2019. Because data on factors associated with this decline are limited, we conducted a retrospective longitudinal study of psychiatric diagnoses of serious suicide attempters before 2012 and after 2019. METHODS: Serious suicide attempters admitted to the critical care medicine (CCM) department of Nippon Medical School Hospital between 2006 and 2017 were included and classified as those before and after the suicide decline in 2012. Chi-square test and residual analysis were used to analyze changes in the proportion of suicide attempters among all patients admitted to CCM and to examine differences in the proportion of psychiatric diagnoses. RESULTS: The proportion of suicide attempters among CCM hospitalized patients decreased overall (χ2 (1) =18.29, p<.01). The proportion of psychiatric diagnoses changed significantly (χ2 (8) =62.21, p<0.001); specifically, it decreased for schizophrenia (residual: -2.28), depressive disorders (residual: -5.39), persistent mood disorders (residual: -3.58), and reaction to stress disorders (residual: -2.73). Depressive disorders decreased and had a large contribution ratio in both sexes. CONCLUSIONS: The decrease in the proportion of attempted suicides among patients admitted to CCM was consistent with the decline in suicides in Japan. Analysis by psychiatric diagnosis confirmed a significant decrease in the proportion of suicide attempts associated with depressive disorders, schizophrenia, and reaction to stress disorders, which were the most common disorders associated with attempted suicide. Depressive disorders made the greatest contribution to the reduction in suicide attempts.

    DOI: 10.1272/jnms.JNMS.2022_89-405

    PubMed

    researchmap

  • Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [F]FE-PE2I.

    Nogami Tsuyoshi, Arakawa Ryosuke, Sakayori Takeshi, Ikeda Yumiko, Okubo Yoshiro, Tateno Amane

    Frontiers in psychiatry   13   799319   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3389/fpsyt.2022.799319

    researchmap

  • A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes. 国際誌

    Tiger Mikael, Gärde Martin, Tateno Amane, Matheson Granville J, Sakayori Takeshi, Nogami Tsuyoshi, Moriya Hiroki,Varnäs Katarina, Arakawa Ryosuke, Okubo Yoshiro

    Journal of affective disorders   294   645 - 651   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Electroconvulsive therapy (ECT) is an effective treatment for depressive disorders, although its molecular mechanism of action is unknown. The serotonin 1B (5-HT) receptor is a potential target for treatment of depression and low 5-HT receptor binding in limbic regions has been reported in previous positron emission tomography (PET) studies of depression.The objective of this longitudinal PET study was to examine the effect of ECT for depression on 5-HT receptor binding. Fifteen hospitalized patients with major depressive episodes were examined with PET and the 5-HT receptor selective radioligand [C]AZ10419369, before and after ECT. Fifteen controls matched for age and sex were examined. Limbic regions with previously reported low 5-HT receptor binding in depression and a dorsal brain stem region were selected.Thirteen patients completed the study according to protocol. Eleven out of thirteen patients responded to ECT. 5-HT receptor binding in hippocampus increased with 30 % after ECT (p=0.021). Using linear mixed effects modelling, we observed increases in 5-HT receptor binding following ECT with a moderate to large effect size, which did not differ significantly between regions.

    DOI: 10.1016/j.jad.2021.07.060

    PubMed

    researchmap

  • PETによる抗うつ薬のモノアミントランスポーター占有率に関する研究—セロトニン/ノルエピネフリントランスポーターを中心に

    松山 敏, 荒川 亮介, 浅見 優子

    BRAIN and NERVE   73 ( 6 )   731 - 736   2021年6月

     詳細を見る

    記述言語:日本語  

    researchmap

  • Effects of anodal-tDCS on implicit motor learning and language-related brain function: An fMRI study.

    Nakashima Soichiro, Koeda Michihiko, Ikeda Yumiko, Hama Tomoko, Funayama Takuya, Akiyama Tomomi, Arakawa Ryosuke, Tateno Amane, Suzuki Hidenori, Okubo Yoshiro

    Psychiatry and clinical neurosciences   2021年2月

     詳細を見る

    記述言語:英語  

    Anodal transcranial Direct Current Stimulation (tDCS) over the left dorsolateral prefrontal cortex (DLPFC) is known as one of the useful applications for improving depressive symptoms or cognitive performance. Antidepressive effects by anodal tDCS over the left DLPFC are expected, but the neural mechanisms of these effects are still unclear. Further, in depression, reduced performance and left prefrontal hypofunction during verbal fluency task (VFT) are generally known. However, few studies have examined the effect of tDCS on the language-related cerebral network. We aimed to investigate whether anodal tDCS at the left DLPFC affects cognitive performance and the neural basis of verbal fluency.Nineteen healthy volunteers participated in this study. The effects of tDCS on cognitive behavior and cerebral function were evaluated by 1) performance and accuracy of implicit/explicit motor learning task (serial reaction time task: SRTT/sequential finger-tapping task: SFTT), and 2) cerebral activation while the subjects were performing VFT by using a functional MRI protocol of a randomized sham-controlled, within-subjects cross-over design.Reaction times of implicit motor learning task were

    DOI: 10.1111/pcn.13208

    researchmap

  • 【バイオマーカーへの期待】薬力学マーカー PETを用いた脳内占有率測定

    荒川 亮介

    精神科   37 ( 6 )   606 - 612   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • Evaluation of dopamine D receptor occupancy by blonanserin using [C]-(+)-PHNO in schizophrenia patients.

    Sakayori Takeshi, Tateno Amane, Arakawa Ryosuke, Kim Woo-Chan, Okubo Yoshiro

    Psychopharmacology   2020年11月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s00213-020-05698-3

    researchmap

  • Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib with other EGFR TKIs.

    Colclough Nicola, Chen Kan,Johns, röm Peter, Strittmatter Nicole, Yan Yumei, Wrigley Gail L, Schou Magnus, Goodwin Richard J A, Varnäs Katarina, Adua Sally J, Zhao Minghui, Nguyen Don X, Maglennon Gareth A, Barton Peter, Atkinson James, Zhang Lin, Janefeldt Annika, Wilson Joanne, Smith Aaron, Takano Akihiro, Arakawa Ryosuke, Kondrashov Mikhail,Malmquist Jonas, Revunov Evgeny, Vazquez-Romero Ana, Moein Mohammad M, Windhorst Albert D,Karp Natasha, Finlay M, Raymond V, Ward Richard A, Yates James W T, Smith Paul D, Farde Lars,Ch

    Clinical cancer research : an official journal of the American Association for Cancer Research   2020年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1158/1078-0432.CCR-19-1871

    researchmap

  • Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo.

    Varnäs Katarina, Finnema Sjoerd J, Johnström Peter, Arakawa Ryosuke, Halldin Christer, Eriksson Lars I, Farde Lars

    British journal of anaesthesia   2020年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.bja.2020.08.052

    researchmap

  • 軽度認知障害から認知症への移行におけるうつ病とアミロイドベータの関連

    山本 憲, 坂寄 健, 荒川 亮介, 舘野 周, 大久保 善朗

    精神神経学雑誌   ( 2020特別号 )   S323 - S323   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本精神神経学会  

    researchmap

  • PETを用いた精神疾患における薬物治療の評価

    荒川 亮介

    メディカル・サイエンス・ダイジェスト   2020年6月

     詳細を見る

    記述言語:日本語  

    researchmap

  • Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression. 国際誌

    Moriya Hiroki, Tiger Mikael, Tateno Amane, Sakayori Takeshi, Masuoka Takahiro, Kim WooChan, Arakawa Ryosuke, Okubo Yoshiro

    Psychiatry and clinical neurosciences   74 ( 8 )   424 - 430   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/pcn.13020

    PubMed

    researchmap

  • First radiolabeling of a ganglioside with a positron emitting radionuclide - in vivo PET demonstrates low exposure of radiofluorinated GM1 in non-human primate brain.

    Revunov Evgeny,Johnström Peter, Arakawa Ryosuke, Malmquist Jonas, Jucaite Aurelija, Defay Tom, Takano Akihiro, Schou Magnus

    ACS chemical neuroscience   2020年4月

     詳細を見る

    記述言語:英語  

    DOI: 10.1021/acschemneuro.0c00161

    researchmap

  • Synthesis, biodistribution and radiation dosimetry of a novel mGluR5 radioligand: [18F]AZD9272.

    Nag Sangram, Varnas Katarina, Arakawa Ryosuke, Jahan Mahabuba, Schou Magnus, Farde Lars,Halldin Christer

    ACS chemical neuroscience   2020年3月

     詳細を見る

    記述言語:英語  

    The metabotropic glutamate receptor subtype mGluR5 has been proposed as a potential drug target for CNS disorders such as anxiety, depression, Parkinson's disease and epilepsy. The AstraZeneca compound AZD9272 has previously been labeled with carbon-11 and used as a PET radioligand for mGluR5 receptor binding. The molecular structure of AZD9272 allows to label the molecule with fluorine-18 without altering the structure. The aim of this study was to develop fluorine-18 analogue of AZD9272 and to examine its binding distribution in the non-human primate brain in vivo as well as to obtain whole body radiation dosimetry. [18F]AZD9272 was successfully synthesized from nitro precursor. The radioligand was stable, with a radiochemical purity of >99% at 2h after formulation in a sterile phosphate buffered solution (pH = 7.4). After injection of [18F]AZD9272 in two cynomolgus monkeys the maximum whole brain radioactivity concentration was 4.9-6.7 % of injected dose (n=2) and PET images showed a pattern of regional radioactivity consistent with that previously obtained for [11C]AZD9272. The percentage of parent radioligand in plasma was 59 and 64% (n=2) at 120 min after injection of [18F]AZ

    DOI: 10.1021/acschemneuro.9b00680

    researchmap

  • PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [F]PF-06684511.

    Arakawa Ryosuke, Takano Akihiro, Stenkrona Per, Stepanov Vladimir, Nag Sangram, Jahan Mahabuba, Grybäck Per, Bolin Martin, Chen Laigao, Zhang Lei, He Ping,Villalobos Anabella, McCarthy Timothy J, Halldin Christer,Varrone Andrea

    European journal of nuclear medicine and molecular imaging   2020年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s00259-020-04739-5

    researchmap

  • Electroconvulsive Therapy Decreases Striatal Dopamine Transporter Binding in Patients with Depression: A Positron Emission Tomography Study with [18F]FE-PE2I

    TakahiroMasuoka, AmaneTateno, TakeshiSakayori, MikaelTiger, WooChanKim, HirokiMoriya, SatoshiUeda, RyosukeArakawa, YoshiroOkubo

    Psychiatry Research: Neuroimaging   2020年

     詳細を見る

    記述言語:英語  

    researchmap

  • PET Technology for Drug Development in Psychiatry

    Ryosuke Arakawa, Akihiro Takano, Christer Halldin

    Neuropsychopharmacol Rep   2020年

     詳細を見る

    記述言語:英語  

    researchmap

  • PETを用いた脳内における向精神薬の評価

    荒川亮介

    臨床精神薬理   23 ( 4 )   2020年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Potential for imaging the high-affinity state of the 5-HT receptor: a comparison of three PET radioligands with differing intrinsic activity.

    Lindberg Anton, Arakawa Ryosuke, Nogami Tsuyoshi, Nag Sangram, Schou Magnus, Elmore Charles S, Farde Lars, Pike Victor W, Halldin Christer

    EJNMMI research   9 ( 1 )   100   2019年11月

     詳細を見る

    記述言語:英語  

    Over the last decade, a few radioligands have been developed for PET imaging of brain 5-HT receptors. The 5-HT receptor is a G-protein-coupled receptor (GPCR) that exists in two different agonist affinity states. An agonist ligand is expected to be more sensitive towards competition from another agonist, such as endogenous 5-HT, than an antagonist ligand. It is of interest to know whether the intrinsic activity of a PET radioligand for the 5-HT receptor impacts on its ability to detect changes in endogenous synaptic 5-HT density. Three high-affinity C-labeled 5-HT PET radioligands with differing intrinsic activity were applied to PET measurements in cynomolgus monkey to evaluate their sensitivity to be displaced within the brain by endogenous 5-HT. For these experiments, fenfluramine was pre-administered at two different doses (1.0 and 5.0 mg/kg, i.v.) to induce synaptic 5-HT release.A dose-dependent response to fenfluramine was detected for all three radioligands. At the highest dose of fenfluramine (5.0 mg/kg, i.v.), reductions in specific binding in the occipital cortex increased with radioligand agonist efficacy, reaching 61% for [C]3. The most antagonistic radioligand show

    DOI: 10.1186/s13550-019-0570-1

    researchmap

  • The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans.

    Varnäs Katarina, Cselényi Zsolt, Arakawa Ryosuke, Nag Sangram, Stepanov Vladimir, Moein Mohammad Mahdi,Johnström Peter, Kingston Lee, Elmore Charles S,Halldin Christer, Farde Lars

    Neuropharmacology   107809   2019年10月

     詳細を見る

  • Identification and Development of an Irreversible Monoacylglycerol Lipase (MAGL) Positron Emission Tomography (PET) Radioligand with High Specificity. 査読

    Zhang L, Butler CR, Maresca KP, Takano A, Nag S, Jia Z, Arakawa R, Piro JR, Samad T, Smith DL, Nason DM, O'Neil S, McAllister L, Schildknegt K, Trapa P, McCarthy TJ, Villalobos A, Halldin C

    Journal of medicinal chemistry   62 ( 18 )   8532 - 8543   2019年9月

     詳細を見る

  • Synthesis and biological evaluation of [18F]fluorovinpocetine, a potential PET radioligand for TSPO imaging.

    Nag S, Krasikova R, Airaksinen A J, Arakawa R, Petukhovd M, Gulyas B

    Bioorganic & medicinal chemistry letters   29 ( 16 )   2270 - 2274   2019年8月

     詳細を見る

  • Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain. 査読

    Takano A, Chen L, Nag S, Brodney MA, Arakawa R, Chang C, Amini N, Doran SD, Dutra JK, McCarthy TJ, Nolan CE, O'Neill BT, Villalobos A, Zhang L, Halldin C

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   60 ( 7 )   992 - 997   2019年7月

     詳細を見る

  • Synthesis and preclinical evaluation of [18F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B. 査読

    Dahl K, Bernard-Gauthier V, Nag S, Varnäs K, Narayanaswami V, Mahdi Moein M, Arakawa R, Vasdev N, Halldin C

    Bioorganic & medicinal chemistry letters   29 ( 13 )   1624 - 1627   2019年7月

     詳細を見る

  • Characterization of [11C]PXT012253 as a PET Radioligand for mGlu4 Allosteric Modulators in Nonhuman Primates. 査読

    Takano A, Nag S, Jia Z, Jahan M, Forsberg A, Arakawa R, Grybäck P, Duvey G, Halldin C, Charvin D

    Molecular imaging and biology   21 ( 3 )   500 - 508   2019年6月

     詳細を見る

  • Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2. 査読

    Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, Asami Y, Hirano Y, Halldin C, Lundberg J

    The international journal of neuropsychopharmacology   22 ( 4 )   278 - 285   2019年4月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/ijnp/pyz003

    PubMed

    researchmap

  • Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography. 査読

    Arakawa R, Takano A, Halldin C

    The international journal of neuropsychopharmacology   22 ( 1 )   53 - 56   2019年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/ijnp/pyy089

    PubMed

    researchmap

  • PETによる抗うつ薬の評価

    荒川亮介

    医学のあゆみ   270 ( 9 )   2019年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Development of a F-labeled PET radioligand for imaging 5-HT receptors: [F]AZ10419096.

    Lindberg Anton, Nag Sangram, Schou Magnus, Arakawa Ryosuke, Nogami Tsuyoshi, Moein Mohammad Mahdi, Elmore Charles S, Pike Victor W, Halldin Christer

    Nuclear medicine and biology   78-79   11 - 16   2019年

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.nucmedbio.2019.10.003

    researchmap

  • Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy. 査読

    Cairns AG, Vazquez-Romero A, Mahdi Moein M, Ådén J, Elmore CS, Takano A, Arakawa R, Varrone A, Almqvist F, Schou M

    ACS chemical neuroscience   9 ( 11 )   2542 - 2547   2018年11月

     詳細を見る

  • Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. 査読

    Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, Takano A, Westman E, Varrone A, Okamura N, Shimada H, Higuchi M, Halldin C, Nordberg A

    European journal of nuclear medicine and molecular imaging   45 ( 9 )   1605 - 1617   2018年7月

     詳細を見る

  • Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. 査読

    Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, Okubo Y

    The international journal of neuropsychopharmacology   21 ( 6 )   522 - 527   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/ijnp/pyy004

    PubMed

    researchmap

  • Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [11C]Raclopride in Non-human Primates 査読

    Ryosuke Arakawa, Lars Farde, Junya Matsumoto, Naoki Kanegawa, Igor Yakushev, Kai-Chun Yang, Akihiro Takano

    Molecular Imaging and Biology   20 ( 2 )   183 - 187   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer New York LLC  

    Purpose: Positron emission tomography (PET) in non-human primates (NHP) is commonly performed under anesthesia, with sevoflurane being a widely used inhaled anesthetic. PET measurement in NHP can be repeated, and a difference in radioligand kinetics has previously been observed between the first and second PET measurement on the same day using sevoflurane anesthesia. In this study, we evaluated the effect of prolonged sevoflurane anesthesia on kinetics and binding potential (BPND) of [11C]raclopride in NHP. Procedures: Three cynomolgus monkeys underwent two to three PET measurements with [11C]raclopride under continuous sevoflurane anesthesia on the same day. The concentration of sevoflurane was adjusted according to the general conditions and safety parameters of the NHP. Time to peak (TTP) radioactivity in the striatum was estimated from time-activity curves (TACs). The BPND in the striatum was calculated by the simplified reference tissue model using the cerebellum as reference region. Results: In each NHP, the TTP became shorter in the later PET measurements than in the first one. Across all measurements (n = 8), concentration of sevoflurane correlated with TTP (Spearman’s ρ = − 0.79, p = 0.03), but not with BPND (ρ = − 0.25, p = 0.55). Conclusions: These data suggest that sevoflurane affects the shape of TACs but has no evident effect on BPND in consecutive PET measurements.

    DOI: 10.1007/s11307-017-1120-8

    Scopus

    PubMed

    researchmap

  • Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. 査読

    Zhang L, Chen L, Dutra JK, Beck EM, Nag S, Takano A, Amini N, Arakawa R, Brodney MA, Buzon LM, Doran SD, Lanyon LF, McCarthy TJ, Bales KR, Nolan CE, O'Neill BT, Schildknegt K, Halldin C, Villalobos A

    Journal of medicinal chemistry   61 ( 8 )   3296 - 3308   2018年4月

     詳細を見る

  • Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain. 査読

    Arakawa R, Stenkrona P, Takano A, Nag S, Maior RS, Halldin C

    EJNMMI research   7 ( 1 )   54   2017年12月

     詳細を見る

  • Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. 査読

    McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C

    Angewandte Chemie (International ed. in English)   56 ( 51 )   16218 - 16222   2017年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1002/anie.201708744

    PubMed

    researchmap

  • PET Quantification of the Norepinephrine Transporter in Human Brain with (S,S)-F-18-FMeNER-D-2 査読

    Sho Moriguchi, Yasuyuki Kimura, Masanori Ichise, Ryosuke Arakawa, Harumasa Takano, Chie Seki, Yoko Ikoma, Keisuke Takahata, Tomohisa Nagashima, Makiko Yamada, Masaru Mimura, Tetsuya Suhara

    JOURNAL OF NUCLEAR MEDICINE   58 ( 7 )   1140 - 1145   2017年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    Norepinephrine transporter (NET) in the brain plays important roles in human cognition and the pathophysiology of psychiatric disorders. Two radioligands, (S,S)-C-11-MRB and (S,S)-F-18-FMeNER-D-2, have been used for imaging NETs in the thalamus and midbrain (including locus coeruleus) using PET in humans. However, NET density in the equally important cerebral cortex has not been well quantified because of unfavorable kinetics with (S,S)-C-11-MRB and defluorination with (S,S)-F-18-FMeNER-D-2, which can complicate NET quantification in the cerebral cortex adjacent to the skull containing defluorinated F-18 radioactivity. In this study, we have established analysis methods of quantification of NET density in the brain including the cerebral cortex using (S,S)-F-18-FMeNER-D-2 PET. Methods: We analyzed our previous (S,S)-F-18-FMeNER-D-2 PET data of 10 healthy volunteers dynamically acquired for 240min with arterial blood sampling. The effects of defluorination on the NET quantification in the superficial cerebral cortex was evaluated by establishing a time stability of NET density estimations with an arterial input 2-tissue-compartment model, which guided the less-invasive reference tissue model and area under the time-activity curve methods to accurately quantify NET density in all brain regions including the cerebral cortex. Results: Defluorination of (S,S)-F-18-FMeNER-D-2 became prominent toward the latter half of the 240-min scan. Total distribution volumes in the superficial cerebral cortex increased with the scan duration beyond 120 min. We verified that 90-min dynamic scans provided a sufficient amount of data for quantification of NET density unaffected by defluorination. Reference tissue model binding potential values from the 90-min scan data and area under the time-activity curve ratios of 70-to 90-min data allowed for the accurate quantification of NET density in the cerebral cortex. Conclusion: We have established methods of quantification of NET densities in the brain including the cerebral cortex unaffected by defluorination using (S,S)-F-18-FMeNER-D-2. These results suggest that we can accurately quantify NET density with a 90-min (S,S)-F-18-FMeNER-D-2 scan in broad brain areas.

    DOI: 10.2967/jnumed.116.178913

    Web of Science

    PubMed

    researchmap

  • Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments. 査読

    Kanamitsu K, Arakawa R, Sugiyama Y, Suhara T, Kusuhara H

    Drug metabolism and pharmacokinetics   31 ( 6 )   395 - 404   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.dmpk.2016.07.003

    Web of Science

    PubMed

    researchmap

  • In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects 査読

    Naoki Kanegawa, Karin Collste, Anton Forsberg, Martin Schain, Ryosuke Arakawa, Aurelija Jucaite, Mats Lekander, Caroline Olgart Hoglund, Eva Kosek, Jon Lampa, Christer Halldin, Lars Farde, Andrea Varrone, Simon Cervenka

    BRAIN BEHAVIOR AND IMMUNITY   54   149 - 157   2016年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Microglia, the resident macrophages in the central nervous system, are thought to be maintained by a local self-renewal mechanism. Although preclinical and in vitro studies have suggested that the brain may contain immune cells also from peripheral origin, the functional association between immune cells in the periphery and brain at physiological conditions is poorly understood.
    We examined 32 healthy individuals using positron emission tomography (PET) and [C-11]PBR28, a radioligand for the 18-kDa translocator protein (TSPO) which is expressed both in brain microglia and blood immune cells. In 26 individuals, two measurements were performed with varying time intervals. In a subgroup of 19 individuals, of which 12 had repeat examinations, leukocyte numbers in blood was measured on each day of PET measurements. All individuals were genotyped for TSPO polymorphism and categorized as high, mixed, and low affinity binders. We assessed TSPO binding expressed as total distribution volume of [C-11]PBR28 in brain and in blood cells.
    TSPO binding in brain was strongly and positively correlated to binding in blood cells both at baseline and when analyzing change between two PET examinations. Furthermore, there was a significant correlation between change of leukocyte numbers and change in TSPO binding in brain, and a trend level correlation to change in TSPO binding in blood cells. These in vivo findings indicate an association between immunological cells in blood and brain via intact BBB, suggesting a functional interaction between these two compartments, such as interchange of peripherally derived cells or a common regulatory mechanism. Measurement of radioligand binding in blood cells may be a way to control for peripheral immune function in PET studies using TSPO as a marker of brain immune activation. (C) 2016 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbi.2016.01.019

    Web of Science

    PubMed

    researchmap

  • Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [C-11]DASB 査読

    Ryosuke Arakawa, Amane Tateno, WooChan Kim, Takeshi Sakayori, Kohei Ogawa, Yoshiro Okubo

    PSYCHIATRY RESEARCH-NEUROIMAGING   251   1 - 6   2016年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER IRELAND LTD  

    Sixteen healthy volunteers were enrolled and divided into four groups according to the single administration of 10 mg or 20 mg escitalopram, 50 mg sertraline, or 20 mg paroxetine. Four positron emission tomography scans with [C-11]DASB were performed on each subject, the first prior to taking the drug, followed by the others at 4, 24, and 48 h after. Serotonin transporter occupancies of the drugs at each time point were calculated. All drugs showed maximum occupancy at 4 h after dosing and then decreasing occupancies with time. Escitalopram and sertraline showed high occupancies of 69.1-77.9% at 4 h, remaining at 52.8-57.8% after 48 h. On the other hand, paroxetine showed relatively low occupancy of 44.6%, then decreasing to 10.3% at 48 h. Escitalopram (both 10 mg and 20 mg) and sertraline (50 mg) showed high and sustained occupancy. Paroxetine (20 mg) showed relatively low and rapidly decreasing occupancy, possibly due to the low plasma concentration by single dosing schedule. Applying the reported concentration of multiple dosing, 20 mg paroxetine will induce over 80% occupancy. The present study suggested that these drugs and doses would be sufficient for the treatment of depression. (C) 2016 Published by Elsevier Ireland Ltd.

    DOI: 10.1016/j.pscychresns.2016.03.006

    Web of Science

    PubMed

    researchmap

  • スウェーデンにおけるナショナルレジストリを用いた医学研究

    臨床精神薬理   18 ( 8 )   2015年

     詳細を見る

    記述言語:日本語  

    researchmap

  • ナショナルデータベースを用いた外来診療における抗不安薬・睡眠薬の処方実態の検討

    荒川亮介, 奥村泰之, 池野敬, 金吉晴, 伊藤弘人

    臨床精神医学   44 ( 7 )   1003 - 1010   2015年

     詳細を見る

    記述言語:日本語  

    researchmap

  • PTSDにおける脳機能画像研究

    荒川亮介

    トラウマティック・ストレス   13 ( 2 )   134 - 138   2015年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Effect of mazindol on extracellular dopamine concentration in human brain measured by PET 査読

    Takeshi Sakayori, Amane Tateno, Ryosuke Arakawa, Yumiko Ikeda, Hidenori Suzuki, Yoshiro Okubo

    PSYCHOPHARMACOLOGY   231 ( 11 )   2321 - 2325   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Mazindol, an appetite suppressant, inhibits the reuptake of dopamine in the synaptic cleft. It has been considered that mazindol might enhance dopamine transmission in the human brain. However, there has been no study that investigated the extracellular dopamine concentration in vivo.
    Using positron emission tomography (PET), we aimed to measure the effect of mazindol on the extracellular dopamine concentration and to evaluate how mazindol affects the dopamine system in the healthy human brain.
    Eleven healthy individuals (six males, five females, age 30.9 +/- 4.9 years) were enrolled in this study. Each participant was scanned with [C-11]raclopride on 1 day without any medicine as baseline condition, and on another day with mazindol as drug condition. In the drug condition, participants took mazindol 0.5 mg (N = 5) or 1.5 mg (N = 6) 2 h before the PET scan. Plasma concentrations of mazindol were measured before the injection of [C-11]raclopride, and urine concentrations of mazindol were measured after the scan.
    After taking mazindol, the calculated decrease in binding potential (Delta BP) in the striatum was 1.74 % for 0.5 mg and 8.14 for 1.5 mg, and the correlation with the blood concentration of mazindol was significant (P = 0.0016, R (2) = 0.69). Delta BP was not significantly correlated with the urine concentration of mazindol (P = 0.84, R (2) = 0.005).
    Mazindol increased the extracellular concentration of dopamine in the human brain, and its effect was dose dependent. A single administration of mazindol, even at usual dosage, elevated dopamine concentration similarly to other addictive drugs, suggesting that the risk of dependence may increase with the mazindol dose.

    DOI: 10.1007/s00213-013-3392-2

    Web of Science

    PubMed

    researchmap

  • Occupancy of serotonin transporter by tramadol: a positron emission tomography study with [C-11] DASB 査読

    Kohei Ogawa, Amane Tateno, Ryosuke Arakawa, Takeshi Sakayori, Yumiko Ikeda, Hidenori Suzuki, Yoshiro Okubo

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   17 ( 6 )   845 - 850   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    Tramadol is used for the treatment of pain, and it is generally believed to activate the -opioid receptor and inhibit serotonin (5-HT) and norepinephrine (NE) transporters. Recent findings from animal experiments suggest that 5-HT reuptake inhibition in brain is related to pain reduction. However, there has been no report of 5-HT transporter (5-HTT) occupancy by tramadol at clinical doses in humans. In the present study, we investigated 5-HTT occupancy by tramadol in five subjects receiving various doses of tramadol by using positron emission tomography (PET) scanning with the radioligand [C-11]DASB. Our data showed that mean 5-HTT occupancies in the thalamus by single doses of tramadol were 34.7% at 50mg and 50.2% at 100mg. The estimated median effective dose (ED50) of tramadol was 98.1mg, and the plasma concentration was 0.33g/ml 2h after its administration; 5-HTT occupancy by tramadol was dose-dependent. We estimated 5-HTT occupancy at 78.7% upon taking an upper limit dose (400mg) of tramadol. The results of the present study support the finding that 5-HTT inhibition is involved in the mechanism underlying the analgesic effect of tramadol in humans, and a clinical dose of tramadol sufficiently inhibits 5-HTT reuptake; this inhibition is similar to that shown by selective serotonin reuptake inhibitors (SSRIs).

    DOI: 10.1017/S1461145713001764

    Web of Science

    PubMed

    researchmap

  • In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I. 査読

    Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H, Okubo Y

    The international journal of neuropsychopharmacology   17 ( 5 )   697 - 703   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1017/S1461145713001612

    Web of Science

    PubMed

    researchmap

  • Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I. 査読

    Shingai Y, Tateno A, Arakawa R, Sakayori T, Kim W, Suzuki H, Okubo Y

    Annals of nuclear medicine   28 ( 3 )   220 - 226   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12149-013-0798-1

    Web of Science

    PubMed

    researchmap

  • Imaging of amyloid deposition in human brain using positron emission tomography and [F-18]FACT: comparison with [C-11] PIB 査読

    Hiroshi Ito, Hitoshi Shinotoh, Hitoshi Shimada, Michie Miyoshi, Kazuhiko Yanai, Nobuyuki Okamura, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Fumitoshi Kodaka, Maiko Ono, Yoko Eguchi, Makoto Higuchi, Toshimitsu Fukumura, Tetsuya Suhara

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING   41 ( 4 )   745 - 754   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Purpose The characteristic neuropathological changes in Alzheimer's disease (AD) are deposition of amyloid senile plaques and neurofibrillary tangles. The F-18-labeled amyloid tracer, [F-18]2-[(2-{(E)-2-[2-(dimethylamino)-1,3-thiazol-5-yl]vinyl}-1,3-benzoxazol-6-yl)oxy]-3-fluoropropan-1-ol (FACT), one of the benzoxazole derivatives, was recently developed. In the present study, deposition of amyloid senile plaques was measured by positron emission tomography (PET) with both [C-11]Pittsburgh compound B (PIB) and [F-18]FACT in the same subjects, and the regional uptakes of both radiotracers were directly compared.
    Methods Two PET scans, one of each with [C-11]PIB and [F-18]FACT, were performed sequentially on six normal control subjects, two mild cognitive impairment (MCI) patients, and six AD patients. The standardized uptake value ratio of brain regions to the cerebellum was calculated with partial volume correction using magnetic resonance (MR) images to remove the effects of white matter accumulation.
    Results No significant differences in the cerebral cortical uptake were observed between normal control subjects and AD patients in [F-18]FACT studies without partial volume correction, while significant differences were observed in [C-11]PIB. After partial volume correction, the cerebral cortical uptake was significantly larger in AD patients than in normal control subjects for [F-18]FACT studies as well as [C-11]PIB. Relatively lower uptakes of [C-11]PIB in distribution were observed in the medial side of the temporal cortex and in the occipital cortex as compared with [F-18]FACT. Relatively higher uptake of [C-11]PIB in distribution was observed in the frontal and parietal cortices.
    Conclusion Since [F-18]FACT might bind more preferentially to dense-cored amyloid deposition, regional differences in cerebral cortical uptake between [C-11]PIB and [F-18]FACT might be due to differences in regional distribution between diffuse and dense-cored amyloid plaque shown in the autoradiographic and histochemical assays of postmortem AD brain sections.

    DOI: 10.1007/s00259-013-2620-7

    Web of Science

    PubMed

    researchmap

  • Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂. 国際誌

    Takano Harumasa, Arakawa Ryosuke, Nogami Tsuyoshi, Suzuki Masayuki, Nagashima Tomohisa, Fujiwara Hironobu, Kimura Yasuyuki, Kodaka Fumitoshi, Takahata Keisuke, Shimada Hitoshi, Murakami Yoshitaka, Tateno Amane, Yamada Makiko, Ito Hiroshi, Kawamura Kazunori, Zhang Ming-Rong, Takahashi Hidehiko, Kato Motoichiro, Okubo Yoshiro, Suhara Tetsuya

    The international journal of neuropsychopharmacology   17 ( 4 )   553 - 60   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Norepinephrine transporter (NET) plays important roles in the treatment of various neuropsychiatric disorders, such as depression and attention deficit hyperactivity disorder (ADHD). Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression. Previous positron emission tomography (PET) studies have reported over 80% serotonin transporter occupancy with clinical doses of selective serotonin reuptake inhibitors (SSRIs), but there has been no report of NET occupancy in patients treated with relatively NET-selective antidepressants. In the present study, we used PET and (S,S)-[18¹⁸F]FMeNER-D₂ to investigate NET occupancies in the thalamus in 10 patients with major depressive disorder taking various doses of nortriptyline, who were considered to be responders to the treatment. Reference data for the calculation of occupancy were derived from age-matched healthy controls. The result showed approximately 50-70% NET occupancies in the brain as a result of the administration of 75-200 mg/d of nortriptyline. The estimated effective dose (ED₅₀) and concentration (EC₅₀) required to induce 50% occupancy was 65.9 mg/d a

    DOI: 10.1017/S1461145713001521

    PubMed

    researchmap

  • Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂. 査読

    Takano H, Arakawa R, Nogami T, Suzuki M, Nagashima T, Fujiwara H, Kimura Y, Kodaka F, Takahata K, Shimada H, Murakami Y, Tateno A, Yamada M, Ito H, Kawamura K, Zhang MR, Takahashi H, Kato M, Okubo Y, Suhara T

    The international journal of neuropsychopharmacology   17 ( 4 )   553 - 560   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1017/S1461145713001521

    Web of Science

    PubMed

    researchmap

  • 救急医療従事者の自殺予防に関する知識と態度

    戸井田 真木, 河西 千秋, 三宅 康史, 岸 泰宏, 大塚 耕太郎, 荒川 亮介, 河嶌 譲

    精神医学   56 ( 1 )   53 - 58   2014年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医学書院  

    日本では,自殺率が高止まりを続けていることから,自殺対策基本法と自殺総合対策大綱が施行・策定され,厚生労働省は,自殺未遂者対策に関連して救急医療従事者を対象とした自殺未遂者ケアのための研修会を実施している。筆者らは,2012年1月から2013年3月の期間に当該の研修会に参加した224名を対象に質問紙を用いた調査を行い,自殺予防対策に関する正しい知識と適切な態度を問うた。その結果,回答者の多くに,80%以上の正答率が示され,知識の設問に比して態度の設問において有意に高い正答率が得られた。また,自殺の予防可能性については97.0%が好ましい回答を示した。一方で,自殺と精神疾患の関連に関する理解の不足や自殺念慮を確認することへの躊躇などが明らかになった。今後,自殺を低減させていくためには,専門教育・専門職生涯教育における自殺予防の導入,そして効果的な自殺予防教育プログラムの開発が必要と考えられた。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00749&link_issn=&doc_id=20140128110008&doc_link_id=10.11477%2Fmf.1405102636&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1405102636&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 震災における脳画像研究

    荒川亮介, 金 吉晴

    精神保健研究   60   97 - 100   2014年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2). 国際誌

    Tsuyoshi Nogami, Harumasa Takano, Ryosuke Arakawa, Tetsuya Ichimiya, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Keisuke Takahata, Masayuki Suzuki, Tomohisa Nagashima, Takaaki Mori, Hitoshi Shimada, Hajime Fukuda, Mizuho Sekine, Amane Tateno, Hidehiko Takahashi, Hiroshi Ito, Yoshiro Okubo, Tetsuya Suhara

    The international journal of neuropsychopharmacology   16 ( 5 )   937 - 43   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Antidepressants used for treatment of depression exert their efficacy by blocking reuptake at serotonin transporters (5-HTT) and/or norepinephrine transporters (NET). Recent studies suggest that serotonin and norepinephrine reuptake inhibitors that block both 5-HTT and NET have better tolerability than tricyclic antidepressants and may have higher efficacy compared to selective serotonin reuptake inhibitors. Previous positron emission tomography (PET) studies have reported >80% 5-HTT occupancy with clinical doses of antidepressants, but there has been no report of NET occupancy in patients treated with antidepressants. In the present study, we investigated both 5-HTT and NET occupancies by PET using radioligands [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2), in six patients, each with major depressive disorder (MDD), using various doses of milnacipran. Our data show that mean 5-HTT occupancy in the thalamus was 33.0% at 50 mg, 38.6% at 100 mg, 60.0% at 150 mg and 61.5% at 200 mg. Mean NET occupancy in the thalamus was 25.3% at 25 mg, 40.0% at 100 mg, 47.3% at 125 mg and 49.9% at 200 mg. Estimated ED(50) was 122.5 mg with the dose for 5-HTT and 149.9 mg for NET. Both 5-HTT and NET occupancies were observed in a dose-dependent manner. Both 5-HTT and NET occupancies were about 40% by milnacipran at 100 mg, the dose most commonly administered to MDD patients.

    DOI: 10.1017/S1461145712001009

    PubMed

    researchmap

  • Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [C-11]DASB and (S,S)-[F-18]FMeNER-D-2 査読

    Tsuyoshi Nogami, Harumasa Takano, Ryosuke Arakawa, Tetsuya Ichimiya, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Keisuke Takahata, Masayuki Suzuki, Tomohisa Nagashima, Takaaki Mori, Hitoshi Shimada, Hajime Fukuda, Mizuho Sekine, Amane Tateno, Hidehiko Takahashi, Hiroshi Ito, Yoshiro Okubo, Tetsuya Suhara

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   16 ( 5 )   937 - 943   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    Antidepressants used for treatment of depression exert their efficacy by blocking reuptake at serotonin transporters (5-HTT) and/or norepinephrine transporters (NET). Recent studies suggest that serotonin and norepinephrine reuptake inhibitors that block both 5-HTT and NET have better tolerability than tricyclic antidepressants and may have higher efficacy compared to selective serotonin reuptake inhibitors. Previous positron emission tomography (PET) studies have reported &gt;80% 5-HTT occupancy with clinical doses of antidepressants, but there has been no report of NET occupancy in patients treated with antidepressants. In the present study, we investigated both 5-HTT and NET occupancies by PET using radioligands [C-11]DASB and (S,S)-[F-18]FMeNER-D-2, in six patients, each with major depressive disorder (MDD), using various doses of milnacipran. Our data show that mean 5-HTT occupancy in the thalamus was 33.0% at 50 mg, 38.6% at 100 mg, 60.0% at 150 mg and 61.5% at 200 mg. Mean NET occupancy in the thalamus was 25.3% at 25 mg, 40.0% at 100 mg, 47.3% at 125 mg and 49.9% at 200 mg. Estimated ED50 was 122.5 mg with the dose for 5-HTT and 149.9 mg for NET. Both 5-HTT and NET occupancies were observed in a dose-dependent manner. Both 5-HTT and NET occupancies were about 40% by milnacipran at 100 mg, the dose most commonly administered to MDD patients.

    DOI: 10.1017/S1461145712001009

    Web of Science

    PubMed

    researchmap

  • Striatal and Extrastriatal Dopamine D-2 Receptor Occupancy by a Novel Antipsychotic, Blonanserin A PET Study With [C-11]Radopride and [C-11]FLB 457 in Schizophrenia 査読

    Amane Tateno, Ryosuke Arakawa, Masaki Okumura, Hajime Fukuta, Kazuyoshi Honjo, Keiichi Ishihara, Hiroshi Nakamura, Shin-ichiro Kumita, Yoshiro Okubo

    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY   33 ( 2 )   162 - 169   2013年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Blonanserin is a novel antipsychotic with high affinities for dopamine D-2 and 5-HT2A receptors, and it was recently approved for the treatment of schizophrenia in Japan and Korea. Although double-blind clinical trials have demonstrated that blonanserin has equal efficacy to risperidone, and with a better profile especially with respect to prolactin elevation, its profile of in vivo receptor binding has not been investigated in patients with schizophrenia. Using positron emission tomography (PET), we measured striatal and extrastriatal dopamine D-2 receptor occupancy by blonanserin in 15 patients with schizophrenia treated with fixed doses of blonanserin (ie, 8, 16, and 24 mg/d) for at least 4 weeks before PET scans, and in 15 healthy volunteers. Two PET scans, 1 with [C-11]raclopride for the striatum and 1 with [C-11]FLB 457 for the temporal cortex and pituitary, were performed on the same day. Striatal dopamine D2 receptor occupancy by blonanserin was 60.8% (3.0%) [mean (SD)] at 8 mg, 73.4% (4.9%) at 16 mg, and 79.7% (2.3%) at 24 mg. The brain/plasma concentration ratio calculated from D-2 receptor occupancy in the temporal cortex and pituitary was 3.38, indicating good blood-brain barrier permeability. This was the first study to show clinical daily dose amounts of blonanserin occupying dopamine D-2 receptors in patients with schizophrenia. The clinical implications obtained in this study were the optimal therapeutic dose range of 12.9 to 22.1 mg/d of blonanserin required for 70% to 80% dopamine D-2 receptor occupancy in the striatum, and the good blood-brain barrier permeability that suggested a relatively lower risk of hyperprolactinemia.

    DOI: 10.1097/JCP.0b013e3182825bce

    Web of Science

    PubMed

    researchmap

  • Training workshop on caring for suicide attempters implemented by the Ministry of Health, Labour and Welfare, Japan. 国際誌

    Maki Hirata, Chiaki Kawanishi, Nene Oyama, Yasushi Miyake, Kotaro Otsuka, Tomoki Yamada, Yasuhiro Kishi, Hiroto Ito, Ryousuke Arakawa

    Psychiatry and clinical neurosciences   67 ( 1 )   64 - 64   2013年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/pcn.12004

    PubMed

    researchmap

  • Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT 査読

    Martin Schain, Miklos Toth, Zsolt Cselenyi, Ryosuke Arakawa, Christer Halldin, Lars Farde, Andrea Varrone

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING   40 ( 2 )   228 - 237   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    The serotonin system is involved in many physiological functions and clinical conditions. Serotonergic neurons originate from the raphe nuclei in the brainstem, and reliable estimates of receptor/transporter availability in the raphe in vivo are thus of interest. Though positron emission tomography (PET) can be used to quantify receptor distribution in the brain, high noise levels prevent reliable estimation of radioligand binding in small regions such as the raphe. For this purpose, parametric imaging in combination with high-resolution PET systems may provide images with reduced noise levels and sufficient contrast for reliable quantification. This study examined the potential to evaluate radioligand binding in brainstem nuclei, and assessed the effect of improved resolution on the outcome measures.
    For comparative purposes, radioligand binding was measured with an ECAT EXACT HR PET system (resolution about 4.5 mm FWHM) and a high-resolution research tomograph (HRRT) system (resolution about 1.5 mm FWHM). Six subjects were examined with both systems on the same day using the serotonin transporter radioligand [C-11]MADAM. Parametric images of binding potential (BP (ND)) were obtained using a wavelet-aided approach. Regions of interest (ROIs) were delineated using a threshold-based semiautomatic delineation procedure for five brainstem structures. Regional BP (ND) values were estimated by applying the ROIs to the parametric images, and the percentage difference in BP (ND) between the systems was calculated.
    Signals for [C-11]MADAM binding were obtained for all five brainstem structures. Overall, the HRRT provided 30-40 % higher BP (ND) values than the HR (p = 0.0017), independent of thresholds used in the ROI delineation procedure.
    The methodology used enabled the estimation of [C-11]MADAM binding in the small nuclei of the brainstem. Differences in the BP (ND) values calculated using data from the two systems were mainly attributable to their differing resolutions. The estimated BP (ND) values provided lower across-subject variability than those previously obtained using compartment analysis. This procedure may therefore facilitate quantitative studies of receptor/transporter availability in the brainstem.

    DOI: 10.1007/s00259-012-2260-3

    Web of Science

    PubMed

    researchmap

  • Effects of menopause on brain structural changes in schizophrenia

    Hajime Fukuta, Itsuo Ito, Amane Tateno, Tsuyoshi Nogami, Yasutomo Taiji, Ryosuke Arakawa, Tetsuya Suhara, Kunihiko Asai, Yoshiro Okubo

    Psychiatry and Clinical Neurosciences   67 ( 1 )   3 - 11   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Aim The aim of this study was to investigate the influences of menopause on brain morphological changes in schizophrenia using magnetic resonance imaging (MRI). Methods Forty female schizophrenia patients, 20 premenopausal and 20 postmenopausal, and 50 female controls underwent cerebral MRI. Optimized voxel-based morphometry was performed with Statistical Parametric Mapping version 5. Results Compared with controls, regional gray matter reductions in schizophrenia patients were observed in the insula, superior temporal gyrus, anterior cingulate, parahippocampal gyrus, and thalamus. Direct comparison between the patient groups showed that the gray matter of postmenopausal patients was significantly smaller when compared with premenopausal patients in the left middle frontal gyrus, and no region had significantly lower gray matter volume in premenopausal patients relative to postmenopausal patients. Significant negative correlation between gray matter volume and the interval after menopause was found in the right superior frontal gyrus in the postmenopause patient group. Conclusion Differential morphological alterations between postmenopausal and premenopausal schizophrenia patients were observed, suggesting that the female hormone plays a protective role against schizophrenia. © 2013 The Authors. Psychiatry and Clinical Neurosciences © 2013 Japanese Society of Psychiatry and Neurology.

    DOI: 10.1111/pcn.12003

    Scopus

    PubMed

    researchmap

  • Effects of menopause on brain structural changes in schizophrenia 査読

    Hajime Fukuta, Itsuo Ito, Amane Tateno, Tsuyoshi Nogami, Yasutomo Taiji, Ryosuke Arakawa, Tetsuya Suhara, Kunihiko Asai, Yoshiro Okubo

    PSYCHIATRY AND CLINICAL NEUROSCIENCES   67 ( 1 )   3 - 11   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Aim The aim of this study was to investigate the influences of menopause on brain morphological changes in schizophrenia using magnetic resonance imaging (MRI). Methods Forty female schizophrenia patients, 20 premenopausal and 20 postmenopausal, and 50 female controls underwent cerebral MRI. Optimized voxel-based morphometry was performed with Statistical Parametric Mapping version 5. Results Compared with controls, regional gray matter reductions in schizophrenia patients were observed in the insula, superior temporal gyrus, anterior cingulate, parahippocampal gyrus, and thalamus. Direct comparison between the patient groups showed that the gray matter of postmenopausal patients was significantly smaller when compared with premenopausal patients in the left middle frontal gyrus, and no region had significantly lower gray matter volume in premenopausal patients relative to postmenopausal patients. Significant negative correlation between gray matter volume and the interval after menopause was found in the right superior frontal gyrus in the postmenopause patient group. Conclusion Differential morphological alterations between postmenopausal and premenopausal schizophrenia patients were observed, suggesting that the female hormone plays a protective role against schizophrenia.

    DOI: 10.1111/pcn.12003

    Web of Science

    PubMed

    researchmap

  • Norepinephrine in the brain is associated with aversion to financial loss

    H. Takahashi, S. Fujie, C. Camerer, R. Arakawa, H. Takano, F. Kodaka, H. Matsui, T. Ideno, S. Okubo, K. Takemura, M. Yamada, Y. Eguchi, T. Murai, Y. Okubo, M. Kato, H. Ito, T. Suhara

    Molecular Psychiatry   18 ( 1 )   3 - 4   2013年1月

     詳細を見る

  • PTSD に対するパロキセチンおよびセルトラリンの臨床試験

    荒川亮介, 金 吉晴

    トラウマティック・ストレス   11 ( 2 )   177 - 180   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本トラウマティック・ストレス学会 ; 2003-  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014089220

  • [Effect of menopause on morphological changes of the brain in schizophrenia]. 査読

    Fukuta H, Ito I, Tateno A, Nogami T, Taiji Y, Arakawa R, Suhara T, Asai K, Okubo Y

    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica   115 ( 12 )   1178 - 1185   2013年

     詳細を見る

  • 東日本大震災における精神保健医療

    荒川亮介, 渡路子, 小見めぐみ, 金吉晴

    救急医学   37 ( 1 )   77 - 81   2013年

     詳細を見る

    記述言語:日本語  

    researchmap

  • 東日本大震災における精神保健医療行政

    荒川亮介

    日精協誌   31   894 - 898   2013年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. 査読

    Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K, Nogami T, Suzuki M, Suhara T

    PloS one   7 ( 9 )   e46488   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0046488

    Web of Science

    PubMed

    researchmap

  • Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. 国際誌

    Takeshi Sasaki, Hiroshi Ito, Yasuyuki Kimura, Ryosuke Arakawa, Harumasa Takano, Chie Seki, Fumitoshi Kodaka, Saori Fujie, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Hironobu Fujiwara, Hidehiko Takahashi, Ryuji Nakao, Toshimitsu Fukumura, Andrea Varrone, Christer Halldin, Toru Nishikawa, Tetsuya Suhara

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   53 ( 7 )   1065 - 73   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    UNLABELLED: (18)F-(E)-N-(3-iodoprop-2E-enyl)-2β-carbofluoroethoxy-3β-(4-methylphenyl)nortropane ((18)F-FE-PE2I) is a new PET radioligand with a high affinity and selectivity for the dopamine transporter (DAT). In nonhuman primates, (18)F-FE-PE2I showed faster kinetics and less production of radiometabolites that could potentially permeate the blood-brain barrier than did (11)C-PE2I. The aims of this study were to examine the quantification of DAT using (18)F-FE-PE2I and to assess the effect of radiometabolites of (18)F-FE-PE2I on the quantification in healthy humans. METHODS: A 90-min dynamic PET scan was obtained for 10 healthy men after intravenous injection of (18)F-FE-PE2I. Kinetic compartment model analysis with a metabolite-corrected arterial input function was performed. The effect of radiometabolites on the quantification was evaluated by time-stability analyses. The simplified reference tissue model (SRTM) method with the cerebellum as a reference region was evaluated as a noninvasive method of quantification. RESULTS: After the injection of (18)F-FE-PE2I, the whole-brain radioactivity showed a high peak (∼3-5 standardized uptake value) and fast washout. The radioactive uptake of (18)F-FE-PE2I in the brain was according to the relative density of the DAT (striatum > midbrain > thalamus). The cerebellum showed the lowest uptake. Tissue time-activity curves were well described by the 2-tissue-compartment model (TCM), as compared with the 1-TCM, for all subjects in all regions. Time stability analysis showed stable estimation of total distribution volume with 60-min or longer scan durations, indicating the small effect of radiometabolites. Binding potentials in the striatum and midbrain were well estimated by the SRTM method, with modest intersubject variability. Although the SRTM method yielded a slight underestimation and overestimation in regions with high and low DAT densities, respectively, binding potentials by the SRTM method were well correlated to the estimates by the indirect kinetic method with 2-TCM. CONCLUSION: (18)F-FE-PE2I is a promising PET radioligand for quantifying DAT. The binding potentials could be reliably estimated in both the striatum and midbrain using both the indirect kinetic and SRTM methods with a scan duration of 60 min. Although radiometabolites of (18)F-FE-PE2I in plasma possibly introduced some effects on the radioactivity in the brain, the effects on estimated binding potential were likely to be small.

    DOI: 10.2967/jnumed.111.101626

    PubMed

    researchmap

  • Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457. 査読

    Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, Kimura Y, Kodaka F, Sasaki T, Nogami T, Suzuki M, Nagashima T, Shimada H, Kato M, Mimura M, Suhara T

    Psychopharmacology   222 ( 1 )   165 - 172   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00213-011-2633-5

    Web of Science

    PubMed

    researchmap

  • Quantification of Dopamine Transporter in Human Brain Using PET with F-18-FE-PE2I 査読

    Takeshi Sasaki, Hiroshi Ito, Yasuyuki Kimura, Ryosuke Arakawa, Harumasa Takano, Chie Seki, Fumitoshi Kodaka, Saori Fujie, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Hironobu Fujiwara, Hidehiko Takahashi, Ryuji Nakao, Toshimitsu Fukumura, Andrea Varrone, Christer Halldin, Toru Nishikawa, Tetsuya Suhara

    JOURNAL OF NUCLEAR MEDICINE   53 ( 7 )   1065 - 1073   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    F-18-(E)-N-(3-iodoprop-2E-enyl)-2 beta-carbofluoroethoxy-3 beta-(4-methylphenyl)nortropane (F-18-FE-PE2I) is a new PET radioligand with a high affinity and selectivity for the dopamine transporter (DAT). In nonhuman primates, F-18-FE-PE2I showed faster kinetics and less production of radiometabolites that could potentially permeate the blood-brain barrier than did C-11-PE2I. The aims of this study were to examine the quantification of DAT using F-18-FE-PE2I and to assess the effect of radiometabolites of F-18-FE-PE2I on the quantification in healthy humans. Methods: A 90-min dynamic PET scan was obtained for 10 healthy men after intravenous injection of F-18-FE-PE2I. Kinetic compartment model analysis with a metabolite-corrected arterial input function was performed. The effect of radiometabolites on the quantification was evaluated by time-stability analyses. The simplified reference tissue model (SRTM) method with the cerebellum as a reference region was evaluated as a noninvasive method of quantification. Results: After the injection of F-18-FE-PE2I, the whole-brain radioactivity showed a high peak (similar to 3-5 standardized uptake value) and fast washout. The radioactive uptake of F-18-FE-PE2I in the brain was according to the relative density of the DAT (striatum &gt; midbrain &gt; thalamus). The cerebellum showed the lowest uptake. Tissue time-activity curves were well described by the 2-tissue-compartment model (TCM), as compared with the 1-TCM, for all subjects in all regions. Time stability analysis showed stable estimation of total distribution volume with 60-min or longer scan durations, indicating the small effect of radiometabolites. Binding potentials in the striatum and midbrain were well estimated by the SRTM method, with modest intersubject variability. Although the SRTM method yielded a slight underestimation and overestimation in regions with high and low DAT densities, respectively, binding potentials by the SRTM method were well correlated to the estimates by the indirect kinetic method with 2-TCM. Conclusion: F-18-FE-PE2I is a promising PET radioligand for quantifying DAT. The binding potentials could be reliably estimated in both the striatum and midbrain using both the indirect kinetic and SRTM methods with a scan duration of 60 min. Although radiometabolites of F-18-FE-PE2I in plasma possibly introduced some effects on the radioactivity in the brain, the effects on estimated binding potential were likely to be small.

    DOI: 10.2967/jnumed.111.101626

    Web of Science

    PubMed

    researchmap

  • Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457. 国際誌

    Takahata Keisuke, Ito Hiroshi, Takano Harumasa, Arakawa Ryosuke, Fujiwara Hironobu, Kimura Yasuyuki, Kodaka Fumitoshi, Sasaki Takeshi, Nogami Tsuyoshi, Suzuki Masayuki, Nagashima Tomohisa, Shimada Hitoshi, Kato Motoichiro, Mimura Masaru, Suhara Tetsuya

    Psychopharmacology   222 ( 1 )   165 - 72   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Second-generation antipsychotics demonstrate clinical efficacy with fewer extrapyramidal side effects compared with first-generation antipsychotics. One of the proposed explanations is the hypothesis of preferential extrastriatal dopamine D₂ receptor occupancy (limbic selectivity) by antipsychotics. In the present study, we focused on aripiprazole, which has a unique pharmacological profile with partial agonism at dopamine D₂ receptors and the minimal risk of extrapyramidal side effects. Previous positron emission tomography (PET) studies using high-affinity radioligands for dopamine D₂ receptors have reported inconsistent results regarding regional differences of dopamine D₂ receptor occupancy by aripiprazole.To test the hypothesis of preferential binding to extrastriatal dopamine D₂ receptors by aripiprazole, we investigated its regional dopamine D₂ receptor occupancies in healthy young subjects.Using PET and two radioligands with different affinities for dopamine D₂ receptors, [¹¹C]raclopride and [¹¹C]FLB457, striatal and extrastriatal dopamine D₂ receptor bindings at baseline and after oral administration of 6 mg aripiprazole were measured in 11 male healthy

    DOI: 10.1007/s00213-011-2633-5

    PubMed

    researchmap

  • [11C]sulpirideとpositron emission tomographyを用いたヒトにおけるsulpirideの動態 査読

    高野 晴成, 荒川 亮介, 伊藤 浩, 須原 哲也

    臨床薬理の進歩   ( 33 )   130 - 138   2012年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公財)臨床薬理研究振興財団  

    臨床で使用されているsulpirideを標識した[11C]sulpirideを開発し、まずサルを用いて基礎的な検討を行った後、ヒト(健常成人2名)を対象に、[11C]sulpirideの全身分布・脳移行性・脳内動態をPETで観察し、さらに臨床用量sulpiride内服後の変化について検討した。結果、サル・ヒトともsulpirideの脳への移行性は低いことが示唆された。臨床用量を内服した場合には、比較的多量のsulpirideが全身(脳外)に曝露されることにより、そのごく一部が脳へ移行し向精神薬としての作用を発現することが推測された。

    researchmap

  • Honesty mediates the relationship between serotonin and reaction to unfairness 査読

    Hidehiko Takahashi, Harumasa Takano, Colin F. Camerer, Takashi Ideno, Shigetaka Okubo, Hiroshi Matsui, Yuki Tamari, Kazuhisa Takemura, Ryosuke Arakawa, Fumitoshi Kodaka, Makiko Yamada, Yoko Eguchi, Toshiya Murai, Yoshiro Okubo, Motoichiro Kato, Hiroshi Ito, Tetsuya Suhara

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   109 ( 11 )   4281 - 4284   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATL ACAD SCIENCES  

    How does one deal with unfair behaviors? This subject has long been investigated by various disciplines including philosophy, psychology, economics, and biology. However, our reactions to unfairness differ from one individual to another. Experimental economics studies using the ultimatum game (UG), in which players must decide whether to accept or reject fair or unfair offers, have also shown that there are substantial individual differences in reaction to unfairness. However, little is known about psychological as well as neurobiological mechanisms of this observation. We combined a molecular imaging technique, an economics game, and a personality inventory to elucidate the neurobiological mechanism of heterogeneous reactions to unfairness. Contrary to the common belief that aggressive personalities (impulsivity or hostility) are related to the high rejection rate of unfair offers in UG, we found that individuals with apparently peaceful personalities (straightforwardness and trust) rejected more often and were engaged in personally costly forms of retaliation. Furthermore, individuals with a low level of serotonin transporters in the dorsal raphe nucleus (DRN) are honest and trustful, and thus cannot tolerate unfairness, being candid in expressing their frustrations. In other words, higher central serotonin transmission might allow us to behave adroitly and opportunistically, being good at playing games while pursuing self-interest. We provide unique neurobiological evidence to account for individual differences of reaction to unfairness.

    DOI: 10.1073/pnas.1118687109

    Web of Science

    PubMed

    researchmap

  • Serotonergic neurotransmission in the living human brain: a positron emission tomography study using [¹¹C]dasb and [¹¹C]WAY100635 in young healthy men. 査読

    Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Kodaka F, Otsuka T, Kato M, Suhara T

    Synapse (New York, N.Y.)   65 ( 7 )   624 - 633   2011年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/syn.20883

    Web of Science

    PubMed

    researchmap

  • 統合失調症患者における抗精神病薬投与前後の線条体ドーパミン生成能の経時的変化 査読

    高野 晴成, 伊藤 浩, 荒川 亮介, 高橋 英彦, 須原 哲也

    核医学   48 ( 2 )   154 - 154   2011年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Relation between Presynaptic and Postsynaptic Dopaminergic Functions Measured by Positron Emission Tomography: Implication of Dopaminergic Tone 査読

    Hiroshi Ito, Fumitoshi Kodaka, Hidehiko Takahashi, Harumasa Takano, Ryosuke Arakawa, Hitoshi Shimada, Tetsuya Suhara

    JOURNAL OF NEUROSCIENCE   31 ( 21 )   7886 - 7890   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NEUROSCIENCE  

    Both presynaptic and postsynaptic dopaminergic functions can be estimated by positron emission tomography (PET). While both presynaptic and postsynaptic dopaminergic functions would be regulated by corresponding genes and related to personality traits, the relation between presynaptic and postsynaptic functions in terms of interindividual variation has hardly been investigated. In the present study, both striatal dopamine D(2) receptor binding and endogenous dopamine synthesis rate were measured in the same healthy subjects using PET with [(11)C]raclopride and L-[beta-(11)C]DOPA, respectively, and these two parameters were compared. Two PET studies with [(11)C] raclopride and L-[beta-(11)C] DOPA were performed sequentially at rest condition on 14 healthy men. For [(11)C] raclopride PET, the binding potential was calculated by the reference tissue model method. For L-[beta-(11)C]DOPAPET, the endogenous dopamine synthesis rate was estimated by graphical analysis. A significant negative correlation was observed between the binding potential of dopamine D(2) receptors and endogenous dopamine synthesis rate (r = -0.66, p &lt; 0.05). Although the interindividual variation of binding potential of [(11)C] raclopride would be due to both the interindividual difference in the receptor density and that in the concentration of endogenous dopamine in the synaptic cleft, the negative correlation between parameters for both presynaptic and postsynaptic functions might indicate a compensative relation between the two functions.

    DOI: 10.1523/JNEUROSCI.6024-10.2011

    Web of Science

    PubMed

    researchmap

  • Central nervous system drug evaluation using positron emission tomography. 査読 国際誌

    Mizuho Sekine, Jun Maeda, Hitoshi Shimada, Tsuyoshi Nogami, Ryosuke Arakawa, Harumasa Takano, Makoto Higuchi, Hiroshi Ito, Yoshiro Okubo, Tetsuya Suhara

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology   9 ( 1 )   9 - 16   2011年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In conventional pharmacological research in the field of mental disorders, pharmacological effect and dose have been estimated by ethological approach and in vitro data of affinity to the site of action. In addition, the frequency of administration has been estimated from drug kinetics in blood. However, there is a problem regarding an objective index of drug effects in the living body. Furthermore, the possibility that the concentration of drug in blood does not necessarily reflect the drug kinetics in target organs has been pointed out. Positron emission tomography (PET) techniques have made progress for more than 20 years, and made it possible to measure the distribution and kinetics of small molecule components in living brain. In this article, we focused on rational drug dosing using receptor occupancy and proof-of-concept of drugs in the drug development process using PET.

    DOI: 10.9758/cpn.2011.9.1.9

    PubMed

    researchmap

  • 抗うつ薬による脳内ノルエピネフリントランスポーター占有率に関するPET研究

    関根 瑞穂, 荒川 亮介, 奥村 正紀, 一宮 哲哉, 舘野 周, 斎藤 卓弥, 伊藤 浩, 須原 哲也, 大久保 善朗

    精神薬療研究年報   43   25 - 26   2011年3月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 抗精神病薬投与時におけるドーパミンD2レセプター占有率の脳内局所差の検討 査読

    伊藤 浩, 荒川 亮介, 高橋 英彦, 高野 晴成, 須原 哲也

    核医学   48 ( 1 )   72 - 72   2011年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Effect of risperidone on high-affinity state of dopamine D-2 receptors: a PET study with agonist ligand [C-11](R)-2-CH3O-N-n-propylnorapomorphine 査読

    Fumitoshi Kodaka, Hiroshi Ito, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Michie Miyoshi, Masaki Okumura, Tatsui Otsuka, Kazuhiko Nakayama, Christer Halldin, Lars Farde, Tetsuya Suhara

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   14 ( 1 )   83 - 89   2011年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    The increased proportion of the high-affinity state of dopamine D-2/3 receptors (D-2,D-high) is assumed to correlate with dopamine hypersensitivity, implying a relationship with psychotic symptoms observed in psychiatric disorders such as schizophrenia. [C-11](R)-2-CH3O-N-n-propylnorapomorphine ([C-11]MNPA), which has an agonistic property to dopamine D-2 receptors (D(2)Rs), is expected to bind preferentially to D-2,D-high. The occupancy of dopamine D(2)Rs by antagonists to receptors has not been investigated using [C-11]MNPA. We compared dopamine D2R occupancies by risperidone, an antagonist to receptors, between [C-11]MNPA and [C-11]raclopride to confirm whether risperidone occupies D-2,D-high and D-2,D-low at almost identical proportions. PET studies were performed on 11 healthy men under resting condition and following oral administration of a single dose of risperidone (0.5-2.0 mg). Striatal receptor occupancy for each radioligand was calculated. The relationship between dose or plasma concentration of risperidone and dopamine D2R occupancy was calculated. Striatal dopamine D2R occupancies measured with [C-11]MNPA and [C-11]raclopride were 22-65% and 24-69%, respectively. In the striatum, ED50 values measured with [C-11]MNPA and [C-11]raclopride were 0.98 and 1.03 mg, respectively. The striatal ED50 values as calculated from plasma concentration were 9.15 ng/ml and 8.01 ng/ml, respectively. Almost identical occupancies and ED50 values were observed between the two radioligands, indicating that risperidone bound to D-2,D-high and D-2,D-low at almost identical proportions in a dose-dependent manner.

    DOI: 10.1017/S1461145710001148

    Web of Science

    PubMed

    researchmap

  • Dopamine D₁ receptors and nonlinear probability weighting in risky choice. 査読

    Takahashi H, Matsui H, Camerer C, Takano H, Kodaka F, Ideno T, Okubo S, Takemura K, Arakawa R, Eguchi Y, Murai T, Okubo Y, Kato M, Ito H, Suhara T

    The Journal of neuroscience : the official journal of the Society for Neuroscience   30 ( 49 )   16567 - 16572   2010年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1523/JNEUROSCI.3933-10.2010

    Web of Science

    PubMed

    researchmap

  • 【新たな抗精神病薬paliperidone徐放錠への期待】 Paliperidone徐放錠の脳内動態特性

    大久保 善朗, 荒川 亮介

    臨床精神薬理   13 ( 11 )   2045 - 2052   2010年11月

     詳細を見る

    記述言語:日本語  

    researchmap

  • Positron emission tomography inter-scanner differences in dopamine D₂ receptor binding measured with [¹¹C]FLB457. 査読

    Kodaka F, Ito H, Shidahara M, Takano H, Takahashi H, Arakawa R, Nakayama K, Suhara T

    Annals of nuclear medicine   24 ( 9 )   671 - 677   2010年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12149-010-0407-5

    Web of Science

    PubMed

    researchmap

  • [18F]FE-PE2Iによる脳内ドーパミントランスポーターの定量 査読

    佐々木 健至, 荒川 亮介, 高野 晴成, 関 千江, 小高 文聰, 藤江 沙織, 伊藤 浩, 須原 哲也

    核医学   47 ( 3 )   369 - 369   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. 査読

    Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, Suhara T

    The Journal of clinical psychiatry   71 ( 9 )   1131 - 1137   2010年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.4088/JCP.08m04307yel

    Web of Science

    PubMed

    researchmap

  • 統合失調症における抗精神病薬治療前後でのドーパミン生成能の変化 査読

    高野 晴成, 伊藤 浩, 荒川 亮介, 高橋 英彦, 須原 哲也

    核医学   47 ( 3 )   369 - 369   2010年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [C-11]DAA1106 査読

    Akihiro Takano, Ryosuke Arakawa, Hiroshi Ito, Amane Tateno, Hidehiko Takahashi, Ryohei Matsumoto, Yoshiro Okubo, Tetsuya Suhara

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   13 ( 7 )   943 - 950   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    Inflammatory/immunological process and glial contribution are suggested in the pathophysiology of schizophrenia. We investigated peripheral benzodiazepine receptors in brains of patients with chronic schizophrenia, which were reported to be located on mitochondria of glial cells, using [C-11]DAA1106 with positron emission tomography. Fourteen patients and 14 age- and sex-matched normal controls participated in this study. PET data were analysed by two-tissue compartment model with metabolite-corrected plasma input. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale. There was no significant difference between [C-11]DAA1106 binding of the cortical regions of normal controls and patients with schizophrenia, whereas the patients showed a positive correlation between cortical [C-11]DAA1106 binding and positive symptom scores. There was also a positive correlation between [C-11]DAA1106 binding and duration of illness. Although the correlations need to be interpreted very cautiously, involvement of glial reaction process in the pathophysiology of positive symptoms or progressive change of schizophrenia might be suggested.

    DOI: 10.1017/S1461145710000313

    Web of Science

    PubMed

    researchmap

  • Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [C-11]WAY 100635 査読

    Tomoyuki Saijo, Akihiro Takano, Tetsuya Suhara, Ryosuke Arakawa, Masaki Okumura, Tetsuya Ichimiya, Hiroshi Ito, Yoshiro Okubo

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   13 ( 6 )   785 - 791   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    In our previous positron emission tomography (PET) study, we demonstrated that ECT decreased dopamine D, receptor in major depressive disorder (MDD). Although many animal studies have focused on the effect of ECT on serotonergic neurotransmission, no human study has directly examined the effect of ECT on brain serotonin [5-hydroxytryptamine (5-HT)] 1A receptors (5-HT(1A)Rs). Using PET with [C-11]WAY 100635, we aimed to evaluate the effect of ECT on 5-HT(1A)Rs in patients with MDD. Nine patients underwent PET scans before and after a series of 6-7 bilateral ECTs. Region-of-interest analysis was performed based on the simplified reference tissue model. There were no significant changes in 5-HT1AR binding in patients between before and after ECT. ECT did not alter [C-11]WAY 100635 binding even after recovery from depressive episode. Although the present finding does not exclude the involvement of brain 5-HT1A systems in the antidepressant action of ECT, it may indicate the involvement of other neurotransmission mechanisms.

    DOI: 10.1017/S1461145709991209

    Web of Science

    PubMed

    researchmap

  • In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study 査読

    Michie Miyoshi, Hitoshi Shinotoh, Zbigniew K. Wszolek, Audrey J. Strongosky, Hitoshi Shimada, Ryosuke Arakawa, Makoto Higuchi, Yoko Ikoma, Fumihiko Yasuno, Kiyoshi Fukushi, Toshiaki Irie, Hiroshi Ito, Tetsuya Suhara

    PARKINSONISM & RELATED DISORDERS   16 ( 6 )   404 - 408   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI LTD  

    Background: Microglial activation and disrupted neurotransmissions may herald symptomatic manifestations in neurodegenerative tauopathies.
    Methods: We investigated microglial activation with [(11)C]DAA1106 positron emission tomography (PET), striatal dopaminergic function with L-[beta-(11)C]dopa PET, acetylcholinesterase (AChE) activity with [(11)C]N-methylpiperidin-4-yl acetate PET, and morphologic brain changes with MRI in three persons (aged 38-41 years) with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), who were presymptomatic gene carriers (PGCs) from an American kindred with pallidopontonigral degeneration. The results from these 3 PGCs were compared with [(11)C]DAA1106 PET results from age-matched 9 healthy volunteers (HV), and with L-[beta-(11)C]dopa and [(11)C]MP4A PET results from 10 HV. Values considered significant were more than 2 SDs greater or less than the normal control mean, as the number of subjects was small for group comparisons.
    Results: Glial activities were increased in the frontal cortex of one PGC, the occipital cortex of two PGCs, and the posterior cingulate cortex of one PGC, although none of the PGCs showed overt glial activation in the brain. Only one of the PGCs showed reduced AChE activity in the temporo-parietal cortex. Three PGCs showed low dopamine synthesis rates in the putamen. Hippocampal atrophy was observed in two PGCs.
    Conclusions: Hippocampal atrophy and striatal dopaminergic dysfunction may be early disease processes in the pathogenesis of FTDP-17. Neuroinflammation may also be an in vivo signature of tau pathology at a prodromal stage, although current PET techniques may not constantly reveal it as the earliest neuroimaging abnormality. (C) 2010 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.parkreldis.2010.04.004

    Web of Science

    PubMed

    researchmap

  • Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[F-18]FMeNER-D-2 査読

    Mizuho Sekine, Ryosuke Arakawa, Hiroshi Ito, Masaki Okumura, Takeshi Sasaki, Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo, Christer Halldin, Tetsuya Suhara

    PSYCHOPHARMACOLOGY   210 ( 3 )   331 - 336   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Central norepinephrine transporter (NET) is one of the main targets of antidepressants. Although the measurement of NET occupancy has been attempted in humans, the outcomes have been inconclusive.
    In this study, the occupancy of NET by different doses of an antidepressant, nortriptyline, was measured using positron emission tomography (PET) with (S,S)-[F-18]FMeNER-D-2.
    PET scans using (S,S)-[F-18]FMeNER-D-2 were performed on six healthy men before and after oral administration of a single oral dose of nortriptyline (10-75 mg). After a bolus i.v. injection of (S,S)-[F-18]FMeNER-D-2, dynamic scanning was performed for 0-90 min, followed by scanning for 120-180 min. The ratio of the thalamus-to-caudate areas under the curve (120-180 min) minus 1 was used as the binding potential (BPND) for NET. NET occupancy was calculated as the percentage reduction of BPND. Venous blood samples were taken to measure the concentrations of nortriptyline just before injection of the tracer and at 180 min after the injection.
    Mean NET occupancies by nortriptyline were 16.4% at 10 mg, 33.2% at 25 mg, and 41.1% at 75 mg. The mean plasma concentration of nortriptyline was less than the lower limit of detection at 10 mg, 23.7 ng/mL at 25 mg, and 50.5 ng/mL at 75 mg. Estimated ED50 was 76.8 mg of administration dose and 59.8 ng/mL of plasma concentration.
    NET occupancy by nortriptyline corresponding to the administration dose of 10-75 mg or plasma concentration was observed from 16% to 41%.

    DOI: 10.1007/s00213-010-1824-9

    Web of Science

    PubMed

    researchmap

  • Electroconvulsive therapy decreases dopamine D₂receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [¹¹C]FLB 457. 査読

    Saijo T, Takano A, Suhara T, Arakawa R, Okumura M, Ichimiya T, Ito H, Okubo Y

    The Journal of clinical psychiatry   71 ( 6 )   793 - 799   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.4088/JCP.08m04746blu

    Web of Science

    PubMed

    researchmap

  • Extrastriatal dopamine D-2 receptor occupancy in olanzapine-treated patients with schizophrenia 査読

    Ryosuke Arakawa, Hiroshi Ito, Masaki Okumura, Akihiro Takano, Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo, Tetsuya Suhara

    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE   260 ( 4 )   345 - 350   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER HEIDELBERG  

    Olanzapine is described as a multi-acting receptor-targeted antipsychotic agent. Although regional differences of dopamine D-2 receptor occupancy, i.e., limbic selectivity, were reported for olanzapine, contradictory results were also reported. We measured dopamine D-2 receptor occupancy of olanzapine in extrastriatal regions in patients with schizophrenia using positron-emission tomography with [C-11]FLB457 and the plasma concentrations of olanzapine. Ten patients with schizophrenia taking 5-20 mg/day of olanzapine participated. Dopamine D-2 receptor occupancy in the temporal cortex ranged from 61.1 to 85.8%, and plasma concentration was from 12.7 to 115.4 ng/ml. The ED50 value was 3.4 mg/day for dose and 10.5 ng/ml for plasma concentration. The ED50 values obtained in this study were quite similar to those previously reported in the striatum. In conclusion, although the subjects and methods were different from previous striatal occupancy studies, these results suggest that limbic occupancy by olanzapine may not be so different from that in the striatum.

    DOI: 10.1007/s00406-009-0082-5

    Web of Science

    PubMed

    researchmap

  • Quantitative analysis of dopamine transporters in human brain using [C-11]PE2I and positron emission tomography: evaluation of reference tissue models 査読

    Chie Seki, Hiroshi Ito, Tetsuya Ichimiya, Ryosuke Arakawa, Yoko Ikoma, Miho Shidahara, Jun Maeda, Akihiro Takano, Hidehiko Takahashi, Yuichi Kimura, Kazutoshi Suzuki, Iwao Kanno, Tetsuya Suhara

    ANNALS OF NUCLEAR MEDICINE   24 ( 4 )   249 - 260   2010年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Dopamine transporter (DAT) is a reuptake carrier of dopamine at presynapse that regulates dopaminergic neural transmission. [C-11]PE2I is a cocaine analog developed as a potent positron emission tomography (PET) ligand for DAT with high selectivity. The aim of this study was to evaluate the applicability of quantification methods using reference tissue models for [C-11]PE2I.
    Dynamic PET scans were performed in 6 young healthy male volunteers after an intravenous bolus injection of [C-11]PE2I. Metabolite-corrected arterial plasma-input functions were obtained. Compartment model analysis and plasma-input Logan analysis were performed to determine the kinetic parameters and distribution volume (V (T)). The distribution volume ratio (DVR) was calculated as the ratio of V (T) in the cerebral region to that in the cerebellum. DVRs were also determined by the original multilinear reference tissue model method (MRTMo) and the simplified reference tissue model method (SRTM), comparing the results with those obtained from graphical analysis using arterial input function. To estimate errors in DVR calculated using the reference tissue model, a simulation study that focused on cerebellar kinetics and scan duration was performed.
    The highest [C-11]PE2I binding was observed in the striatum, followed by the midbrain and thalamus. The 2-tissue model was preferable to the 1-tissue model for describing the [C-11]PE2I kinetics in the cerebellum. Both the measured and 90-min simulated data showed that reference tissue models caused an underestimation of DVR in the striatum. The simulation showed that 90-min scan duration was insufficient when cerebellar kinetics was described as a 1-tissue model. Nevertheless, DVR values determined by MRTMo and SRTM were in good agreement with those by the graphical approach in other lower binding regions.
    Due to the [C-11]PE2I kinetics in the cerebellum and limited scan duration for C-11, MRTMo and SRTM underestimated the striatal DVR. Despite this limitation, the present study demonstrated the applicability of reference tissue models. Since DAT in the midbrain and thalamus is of interest in the pathophysiology of neuropsychiatric disease, this noninvasive quantitative analysis will be useful for clinical investigations.

    DOI: 10.1007/s12149-010-0364-z

    Web of Science

    PubMed

    researchmap

  • Dopamine D-2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects 査読

    Ryosuke Arakawa, Hiroshi Ito, Akihiro Takano, Masaki Okumura, Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo, Tetsuya Suhara

    PSYCHOPHARMACOLOGY   209 ( 4 )   285 - 290   2010年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Perospirone is a novel second-generation antipsychotic drug with high affinity to dopamine D-2 receptor and short half-life of plasma concentration. There has been no investigation of dopamine D-2 receptor occupancy in patients with schizophrenia and the time course of occupancy by antipsychotics with perospirone-like properties.
    We investigated dopamine D-2 receptor occupancy by perospirone in patients with schizophrenia and the time course of occupancy in healthy subjects.
    Six patients with schizophrenia taking 16-48 mg/day of perospirone participated. Positron emission tomography (PET) scans using [C-11]FLB457 were performed on each subject, and dopamine D-2 receptor occupancies were calculated. Moreover, baseline and three serial PET using [C-11]raclopride were performed at 1.5, 8, and 25.5 h after administration of a single dose of 16 mg of perospirone on four healthy male subjects, and occupancy was calculated for each scan.
    Dopamine D-2 receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%. Especially, occupancy in two patients who took 16 mg of perospirone 2.5 h before PET was over 70%. Mean occupancy in the striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at 8 h, and 31.9% at 25.5 h after administration.
    Sixteen milligrams of perospirone caused over 70% dopamine D-2 receptor occupancy near its peak level, and then occupancy dropped to about half after 22 h. The time courses of receptor occupancy and plasma concentration were quite different. This single dosage may be sufficient for the treatment of schizophrenia and might be useful as a new dosing schedule choice.

    DOI: 10.1007/s00213-010-1783-1

    Web of Science

    PubMed

    researchmap

  • 抗うつ薬による脳内ノルエピネフリントランスポーター占有率に関するPET研究

    関根 瑞保, 荒川 亮介, 奥村 正紀, 一宮 哲哉, 舘野 周, 斎藤 卓弥, 伊藤 浩, 須原 哲也

    精神薬療研究年報   42   25 - 26   2010年3月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 精神疾患の病態解明と客観的治療評価に向けたPETイメージング研究

    須原 哲也, 大久保 善朗, 安野 史彦, 高野 晶寛, 高橋 英彦, 荒川 亮介, 一宮 哲哉, 伊藤 浩, 加藤 元一郎, 樋口 真人

    日本医師会雑誌   138 ( 12 )   2569 - 2574   2010年3月

     詳細を見る

    記述言語:日本語  

    researchmap

  • No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [¹¹C]verapamil. 査読

    Arakawa R, Ito H, Okumura M, Morimoto T, Seki C, Takahashi H, Takano A, Suhara T

    Annals of nuclear medicine   24 ( 2 )   83 - 87   2010年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12149-009-0336-3

    Web of Science

    PubMed

    researchmap

  • Contribution of Dopamine D1 and D2 Receptors to Amygdala Activity in Human 査読

    Hidehiko Takahashi, Harumasa Takano, Fumitoshi Kodaka, Ryosuke Arakawa, Makiko Yamada, Tatsui Otsuka, Yoshiyuki Hirano, Hideyuki Kikyo, Yoshiro Okubo, Motoichiro Kato, Takayuki Obata, Hiroshi Ito, Tetsuya Suhara

    JOURNAL OF NEUROSCIENCE   30 ( 8 )   3043 - 3047   2010年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NEUROSCIENCE  

    Several animal studies have demonstrated functional roles of dopamine (DA) D1 and D2 receptors in amygdala activity. However, the contribution of DA D1 and D2 receptors to amygdala response induced by affective stimuli in human is unknown. To investigate the contribution of DA receptor subtypes to amygdala reactivity in human, we conducted a multimodal in vivo neuroimaging study in which DA D1 and D2 receptor bindings in the amygdala were measured with positron emission tomography (PET), and amygdala response induced by fearful faces was assessed by functional magnetic resonance imaging (fMRI) in healthy volunteers. We used multimodality voxelwise correlation analysis between fMRI signal and DA receptor binding measured by PET. DA D1 binding in the amygdala was positively correlated with amygdala signal change in response to fearful faces, but DA D2 binding in the amygdala was not related to amygdala signal change. DA D1 receptors might play a major role in enhancing amygdala response when sensory inputs are affective.

    DOI: 10.1523/JNEUROSCI.5689-09.2010

    Web of Science

    PubMed

    researchmap

  • Measurement error analysis for the determination of dopamine D-2 receptor occupancy using the agonist radioligand [C-11]MNPA 査読

    Miho Shidahara, Hiroshi Ito, Tatsui Otsuka, Yoko Ikoma, Ryosuke Arakawa, Fumitoshi Kodaka, Chie Seki, Harumasa Takano, Hidehiko Takahashi, Federico E. Turkheimer, Yuichi Kimura, Iwao Kanno, Tetsuya Suhara

    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM   30 ( 1 )   187 - 195   2010年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    The purpose of this study is to investigate errors in quantitative analysis for estimating dopamine D-2 receptor occupancy of antipsychotics with agonist radioligand [C-11]MNPA by numerical simulation, with particular attention to the validity of a quantitative approach based on the use of a reference region. Synthetic data were validated using clinical data combined with a bootstrap approach. Time-activity curves (TACs) of [C-11]MNPA were simulated, and the reliability of binding potential (BPND) and occupancy estimated by nonlinear least square (NLS) fitting and a simplified reference tissue model (SRTM) were investigated for various noise levels and scan durations. In the human positron emission tomography (PET) study with and without antipsychotic, risperidone, the uncertainty of BPND and occupancy estimated by SRTM was investigated using resampled TACs based on bootstrap approach with weighted residual errors of fitting. For both NLS and SRTM, it was possible to have &lt; 3% of bias in occupancy estimates of [C-11]MNPA by 60 mins. However, shortened scan duration degrades the quantification of very small binding potentials, especially in case of SRTM. Observations were replicated on the clinical data. Results showed that dopamine D-2 receptor occupancy by antipsychotics can be estimated precisely in region of interest analysis by SRTM with a longer than 60-min [C-11]MNPA PET scan duration. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 187-195; doi: 10.1038/jcbfm.2009.193; published online 16 September 2009

    DOI: 10.1038/jcbfm.2009.193

    Web of Science

    PubMed

    researchmap

  • Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: A [C-11]DASB PET study 査読

    Ryohei Matsumoto, Masanori Ichise, Hiroshi Ito, Tomomichi Ando, Hidehiko Takahashi, Yoko Ikoma, Jun Kosaka, Ryosuke Arakawa, Yota Fujimura, Miho Ota, Akihiro Takano, Kenji Fukui, Kazuhiko Nakayama, Tetsuya Suhara

    NEUROIMAGE   49 ( 1 )   121 - 126   2010年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The serotonin transporter (5-HTT) and other markets of the serotonergic system have been of interest in the pathophysiology of obsessive-compulsive disorder (OCD). Previous studies using single photon emission computed tomography (SPECT) with [I-123]beta-CIT or positron emission tomography (PET) with [C-11]McN5652 have not shown consistent findings about 5-HTT in OCD patients. The aim of the present study was to investigate 5-HTT binding using [C-11]DASB, which has higher selectivity or specific binding-to-nonspecific binding ratios for 5-HTT compared to the aforementioned radioligands. Four drug-naive and 6 drug-free patients with OCD who were free of comorbid depression and 18 gender and age-matched healthy subjects underwent PET scans with [C-11]DASB. The severity of OCD was assessed by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (mean +/- SD: 22 +/- 7.6, range: 7-32). The binding potential (BPND) of [C-11]DASB was calculated using a two-parameter multilinear reference tissue model (MRTM2). The parametric images of BPND were analyzed using a statistical parametric mapping system. Significant reductions of BPND were observed in the right posterior and left anterior insular cortices in patients with OCD compared to controls. Region-of-interest analysis has also confirmed significant reduction of BPND in the insular cortex. Although significantly reduced BPND in the orbitolfrontal cortex was also observed in patients with OCD compared to controls, this finding should be considered with caution because of the very low 5-HTT binding in the region. On the other hand, no significant correlation was observed between the Y-BOCS score and BPND. The change in [C-11]DASB binding in the insular cortex suggests that dysfunction of the serotonergic system in the limbic area might be involved in the pathophysiology of OCD. (c) 2009 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.neuroimage.2009.07.069

    Web of Science

    PubMed

    researchmap

  • 精神疾患の病態解明と客観的治療評価に向けたPETイメージング研究

    須原 哲也, 大久保 善朗, 安野 史彦, 高野 晶寛, 高橋 英彦, 荒川 亮介, 一宮 哲哉, 伊藤 浩, 加藤 元一郎, 樋口 真人

    最新医学   65 ( 1 )   122 - 153   2010年1月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 統合失調症・うつ病の分子イメージング

    荒川亮介

    臨床放射線   2010年

     詳細を見る

    記述言語:日本語  

    researchmap

  • 統合失調症とうつ病の分⼦イメージング

    野上毅, 荒川亮介, 須原哲也

    PET journal   10 ( 10 )   31 - 33   2010年

     詳細を見る

    記述言語:日本語   出版者・発行元:寺田国際事務所先端医療技術研究所  

    researchmap

  • ノルアドレナリン系のPETイメージング

    荒川亮介

    精神科   16 ( 3 )   255 - 257   2010年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Regional cerebral blood flow in patients with orally localized somatoform pain disorder: a single photon emission computed tomography study 査読

    Hiroyuki Karibe, Ryosuke Arakawa, Amane Tateno, Sunao Mizumura, Tomoo Okada, Takashi Ishii, Katsuo Oshima, Mitsuhiro Ohtsu, Isao Hasegawa, Yoshiro Okubo

    PSYCHIATRY AND CLINICAL NEUROSCIENCES   64 ( 5 )   476 - 482   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Aim:
    Somatoform pain disorder is characterized by persistent and chronic pain at one or more sites without an associated general medical condition and in which psychological factors are thought to play a role. This study aimed to investigate the pathological features of somatoform pain disorder localized to the oral region by single photon emission computed tomography (SPECT).
    Methods:
    Ten patients (nine females and one male; average age 55.0 +/- 14.4 years) having somatoform pain disorder with oral symptoms participated. SPECT was performed using N-isopropyl-4-[123I] iodoamphetamine intravenous injections, and regional cerebral blood flow (rCBF) was assessed by three-dimensional stereotactic surface projections. We also selected 12 healthy individuals (seven females and five males; average age 61.8 +/- 13.2 years) to act as controls.
    Results:
    Both the patient and control groups showed no atrophy or infarction on CT or magnetic resonance imaging. The patient group showed higher rCBF in the subcortical area, especially in the thalamus and cingulate gyri, than the control group. In contrast, the patient group showed lower rCBF in the bilateral frontal and occipital lobes as well as in the left temporal lobe.
    Conclusions:
    These results suggest that the biological process involved in somatoform pain disorder of the oral region is characterized by changes in limbic and cortical functions. The finding that somatoform pain disorder with oral symptoms is associated with brain functional changes will help to develop treatment regimes for this disorder and clarify the underlying pathology.

    DOI: 10.1111/j.1440-1819.2010.02119.x

    Web of Science

    PubMed

    researchmap

  • Effects of the Antipsychotic Risperidone on Dopamine Synthesis in Human Brain Measured by Positron Emission Tomography with L-[beta-C-11]DOPA: A Stabilizing Effect for Dopaminergic Neurotransmission? 査読

    Hiroshi Ito, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Michie Miyoshi, Fumitoshi Kodaka, Masaki Okumura, Tatsui Otsuka, Tetsuya Suhara

    JOURNAL OF NEUROSCIENCE   29 ( 43 )   13730 - 13734   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NEUROSCIENCE  

    Effects of antipsychotic drugs have widely been considered to be mediated by blockade of postsynaptic dopamine D-2 receptors. Effects of antipsychotics on presynaptic functions of dopaminergic neurotransmission might also be related to therapeutic effects of antipsychotics. To investigate the effects of antipsychotics on presynaptic functions of dopaminergic neurotransmission in relation with occupancy of dopamine D-2 receptors, changes in dopamine synthesis capacity by antipsychotics and occupancy of dopamine D-2 receptors were measured by positron emission tomography (PET) in healthy men. PET studies using [C-11] raclopride and L-[beta-C-11] DOPA were performed under resting condition and oral administration of single dose of the antipsychotic drug risperidone on separate days. Although occupancy of dopamine D-2 receptors corresponding dose of risperidone was observed, the changes in dopamine synthesis capacity by the administration of risperidone were not significant, nor was the relation between the occupancy of dopamine D-2 receptors and these changes. A significant negative correlation was observed between the baseline dopamine synthesis capacity and the changes in dopamine synthesis capacity by risperidone, indicating that this antipsychotic can be assumed to stabilize the dopamine synthesis capacity. The therapeutic effects of risperidone in schizophrenia might be related to such stabilizing effects on dopaminergic neurotransmission responsivity.

    DOI: 10.1523/JNEUROSCI.4172-09.2009

    Web of Science

    PubMed

    researchmap

  • Increase in thalamic binding of [C-11]PE2I in patients with schizophrenia: A positron emission tomography study of dopamine transporter 査読

    Ryosuke Arakawa, Tetsuya Ichimiya, Hiroshi Ito, Akihiro Takano, Masaki Okumura, Hidehiko Takahashi, Harumasa Takano, Fumihiko Yasuno, Motoichiro Kato, Yoshiro Okubo, Tetsuya Suhara

    JOURNAL OF PSYCHIATRIC RESEARCH   43 ( 15 )   1219 - 1223   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD  

    Previous in vivo imaging studies reported no difference in dopamine transporter (DAT) bindings in the striatum between control subjects and patients with schizophrenia. However, as the signals of radioligands with moderate affinity were insufficient for allowing the evaluation of small amounts of DAT, DAT binding in extrastriatal regions has not been determined. Positron emission tomography scanning using [C-11]PE2I was performed on eight patients with schizophrenia and twelve normal control subjects. Binding potential (BPND) for DAT in the caudate, putamen, thalamus and substantia nigra was calculated, using the cerebellum as reference region. In patients with schizophrenia, clinical symptoms were evaluated by Positive and Negative Syndrome Scale (PANSS). BPND in the thalamus of patients with schizophrenia was significantly higher than in control subjects (P = 0.044). In patients with schizophrenia, there were significantly positive correlations between BPND in the thalamus and total (r = 0.75), positive (r = 0.78) and negative PANSS scores (r = 0.82). Altered DAT in the thalamus might be related to the pathophysiology and clinical symptoms of schizophrenia. (C) 2009 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.jpsychires.2009.04.009

    Web of Science

    PubMed

    researchmap

  • (S,S)-[18F]FMeNER-D2を用いた抗うつ薬のノルエピネフリントランスポーター占有率測定

    関根 瑞保, 荒川 亮介, 伊藤 浩, 奥村 正紀, 高橋 英彦, 高野 晴成, 大久保 善朗, 須原 哲也

    核医学   46 ( 3 )   310 - 310   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • 末梢性ベンゾジアゼピン受容体測定用放射性リガンド[11C]AC5216の定量法の検討 査読

    三好 美智恵, 伊藤 浩, 荒川 亮介, 高橋 英彦, 高野 晴成, 関 千江, 樋口 真人, 中尾 隆士, 福村 利光, 松本 昌泰, 須原 哲也

    核医学   46 ( 3 )   311 - 311   2009年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET with (11)C-AC-5216 査読

    Michie Miyoshi, Hiroshi Ito, Ryosuke Arakawa, Hidehiko Takahashi, Harumasa Takano, Makoto Higuchi, Masaki Okumura, Tatsui Otsuka, Fumitoshi Kodaka, Mizuho Sekine, Takeshi Sasaki, Saori Fujie, Chie Seki, Jun Maeda, Ryuji Nakao, Ming-Rong Zhang, Toshimitsu Fukumura, Masayasu Matsumoto, Tetsuya Suhara

    JOURNAL OF NUCLEAR MEDICINE   50 ( 7 )   1095 - 1101   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    Peripheral benzodiazepine receptor (PBR) is upregulated in activated glial cells and is therefore a useful biomarker for inflammation in the brain and neurodegenerative disorders. We developed a new PET radioligand, (11)C-AC-N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-pheyl-7,8-dihydro-9H-purin-9-yl)acetamide ((11)C-AC-5216), that allows the imaging and quantification of PBRs in monkey and mouse brains. The aim of this study was to evaluate a quantification method of (11)C-AC-5216 binding in the human brain. Methods: A 90-min dynamic PET scan was obtained for each of 12 healthy men after an intravenous injection of (11)C-AC-5216. Regions of interest were drawn on several brain regions. Binding potential, compared with nondisplaceable uptake (BP(ND)), was calculated by a nonlinear least-squares fitting (NLS) method with the 2-tissue-compartment model, and total volume of distribution (V(T)) was estimated by NLS and graphical analysis methods. Results: BPND was highest in the thalamus (4.6 +/- 1.0) and lowest in the striatum (3.5 +/- 0.7). V(T) obtained by NLS or graphical analysis showed regional distribution similar to BPND. However, there was no correlation between BPND and VT because of the interindividual variation of K(1)/k(2). BPND obtained with data from a scan time of 60 min was in good agreement with that from a scan time of 90 min (r = 0.87). Conclusion: Regional distribution of (11)C-AC-5216 was in good agreement with previous PET studies of PBRs in the human brain. BP(ND) is more appropriate for estimating (11)C-AC-5216 binding than is VT because of the interindividual variation of K(1)/k(2). (11)C-AC-5216 is a promising PET ligand for quantifying PBR in the human brain.

    DOI: 10.2967/jnumed.109.062554

    Web of Science

    PubMed

    researchmap

  • No regional difference in dopamine D-2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study 査読

    Hiroshi Ito, Ryosuke Arakawa, Hidehiko Takahashi, Harumasa Takano, Masaki Okumura, Tatsui Otsuka, Yoko Ikoma, Miho Shidahara, Tetsuya Suhara

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   12 ( 5 )   667 - 675   2009年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    The effects of antipsychotic drugs have generally been considered to be mediated by blockade of dopamine D-2 receptors. The concept of limbic and cortical selectivity of second-generation antipsychotics, i.e. higher dopamine D-2 receptor occupancy in the cerebral cortices than in the striatum, has been Suggested to explain their clinical efficacy with lower incidence of extrapyramidal side-effects. In this study, regional distribution of dopamine D-2 receptor occupancy by risperidone was determined in order to elucidate the limbic and cortical selectivity of second-generation antipsychotics. Striatal and extrastriatal dopamine D-2 receptor binding at baseline and after oral administration of 2 mg risperidone were measured in ten healthy men by positron emission tomography (PET) using different tracers with different affinity for the receptors, [C-11]raclopride and [C-11]FLB 457, respectively. Striatal and extrastriatal occupancies of dopamine D-2 receptors were calculated for each brain region. Occupancies of dopamine D-2 receptors were about 70%, and 60% in the striatum and extrastriatum, respectively. A simulation study showed that non-negligible specific binding in the reference region (cerebellum), could cause systemic underestimation of occupancy in [C-11]FLB 457 PET studies, indicating that occupancies in both the striatum and extrastriatum may not have differed. Among the extrastriatal regions including limbic and neocortical regions, no significant regional differences in dopamine D receptor occupancy were observed. Thus, limbic and cortical selectivity was not observed by one of the second-generation antipsychotics, risperidone.

    DOI: 10.1017/S1461145708009577

    Web of Science

    PubMed

    researchmap

  • Quantitative PET Analysis of the Dopamine D-2 Receptor Agonist Radioligand C-11-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain 査読

    Tatsui Otsuka, Hiroshi Ito, Christer Halldin, Hidehiko Takahashi, Harumasa Takano, Ryosuke Arakawa, Masaki Okumura, Fumitoshi Kodaka, Michie Miyoshi, Mizuho Sekine, Chie Seki, Ryuji Nakao, Kazutoshi Suzuki, Sjoerd Finnema, Yoshio Hirayasu, Tetsuya Suhara, Lars Farde

    JOURNAL OF NUCLEAR MEDICINE   50 ( 5 )   703 - 710   2009年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    It has been demonstrated in vitro that the dopamine D-2 receptor has 2 interconvertible affinity states for endogenous dopamine, referred to as the high-and the low-affinity states. C-11-(R)-2-CH3O- N-n-propylnorapomorphine (C-11-MNPA) is a new agonist radioligand for in vivo imaging of the high-affinity state of dopamine D-2 receptors using PET. In the present study, the kinetics of C-11-MNPA were examined for the first time, to our knowledge, in the human brain and analyzed using quantitative approaches with or without an arterial input function. Methods: A 90-min dynamic PET scan was obtained for 10 healthy men after an intravenous injection of C-11-MNPA. The binding potential (BPND) was calculated using the indirect kinetic method, a kinetic compartment analysis with a metabolite-corrected arterial input function. BPND was also calculated by the simplified reference tissue model (SRTM) and transient equilibrium methods, both with the cerebellum as the reference brain region. The results of the quantitative methods were compared in a cross-validation approach. Results: The highest regional radioactivity was observed in the putamen. BPND values obtained by kinetic analysis were 0.82 +/- 0.09, 0.59 +/- 0.11, and 0.28 +/- 0.06, respectively, in the putamen, caudate, and thalamus. BPND values obtained by the SRTM and transient equilibrium methods were in good agreement with those obtained by the indirect kinetic method (r = 0.98 and r - 0.93, respectively). For all quantification methods, the BPND values based on data acquired from 0 to 60 min were in good agreement with those based on data acquired from 0 to 90 min (r = 0.90-0.99). Conclusion: The regional distribution of C-11-MNPA binding was in good agreement with previous PET studies of dopamine D-2 receptors in the human brain using antagonist radioligands. The results support routine use of the SRTM and transient equilibrium methods, that is, methods that do not require an arterial input function and need a scan time of only about 60 min. C-11-MNPA should thus be useful for clinical research on the pathophysiology of neuropsychiatric disorders and estimation of dopamine D-2 receptor occupancy by dopaminergic drugs.

    DOI: 10.2967/jnumed.108.058503

    Web of Science

    PubMed

    researchmap

  • Regional dopamine synthesis in patients with schizophrenia using L-[beta-C-11]DOPA PET 査読

    Shoko Nozaki, Motoichiro Kato, Harumasa Takano, Hiroshi Ito, Hidehiko Takahashi, Ryosuke Arakawa, Masaki Okumura, Yota Fujimura, Ryohei Matsumoto, Miho Ota, Akihiro Takano, Akihiko Otsuka, Fumihiko Yasuno, Yoshiro Okubo, Haruo Kashima, Tetsuya Suhara

    SCHIZOPHRENIA RESEARCH   108 ( 1-3 )   78 - 84   2009年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE BV  

    The dopamine hypothesis has been the most widely known theory concerning schizophrenia. However, the exact mechanism including presynaptic dopaminergic activity and its relationship with symptom severity still remains to be revealed. We measured presynaptic dopamine synthesis using positron emission tomography (PET) with L-[beta-C-11]DOPA in 18 patients with schizophrenia (14 drug-naive and 4 drug-free patients) and 20 control participants. Dopamine synthesis rates, expressed as k(i) values, were obtained using a graphical method, and the occipital cortex was used as reference region. Regions of interest were placed on the prefrontal cortex, temporal cortex, anterior cingulate, parahippocampus, thalamus, caudate nucleus, and putamen. Psychopathology was assessed with the Positive and Negative Symptom Scale (PANSS). We found significantly higher ki values in patients than in controls in the left caudate nucleus, but not in the other regions. The ki values in the thalamus exhibited a significant positive correlation with the PANSS total scores. Furthermore, a significant positive correlation was observed between the PANSS positive subscale scores and ki values in the right temporal cortex. Patients with schizophrenia showed higher dopamine synthesis in the left caudate nucleus, and dopaminergic transmission in the thalamus and right temporal cortex might be implicated in the expression of symptoms in schizophrenia. (C) 2008 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.schres.2008.11.006

    Web of Science

    PubMed

    researchmap

  • 抗精神病薬による下垂体ドーパミンD2受容体阻害作用の定量的評価

    荒川 亮介, 伊藤 浩, 奥村 正紀, 大久保 善朗, 須原 哲也

    精神薬療研究年報   28 - 29   2009年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Differential Contributions of Prefrontal and Hippocampal Dopamine D-1 and D-2 Receptors in Human Cognitive Functions 査読

    Hidehiko Takahashi, Motoichiro Kato, Harumasa Takano, Ryosuke Arakawa, Masaki Okumura, Tatsui Otsuka, Fumitoshi Kodaka, Mika Hayashi, Yoshiro Okubo, Hiroshi Ito, Tetsuya Suhara

    JOURNAL OF NEUROSCIENCE   28 ( 46 )   12032 - 12038   2008年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NEUROSCIENCE  

    Dopamine D-1 receptors in the prefrontal cortex (PFC) are important for prefrontal functions, and it is suggested that stimulation of prefrontal D-1 receptors induces an inverted U-shaped response, such that too little or too much D-1 receptor stimulation impairs prefrontal functions. Less is known of the role of D-2 receptors in cognition, but previous studies showed that D-2 receptors in the hippocampus (HPC) might play some roles via HPC-PFC interactions. We measured both D-1 and D-2 receptors in PFC and HPC using positron emission tomography in healthy subjects, with the aim of elucidating how regional D-1 and D-2 receptors are differentially involved in frontal lobe functions and memory. We found an inverted U-shaped relation between prefrontal D-1 receptor binding and Wisconsin Card Sorting Test performance. However, prefrontal D-2 binding has no relation with any neuropsychological measures. Hippocampal D-2 receptor binding showed positive linear correlations not only with memory function but also with frontal lobe functions, but hippocampal D-1 receptor binding had no association with any memory and prefrontal functions. Hippocampal D-2 receptors seem to contribute to local hippocampal functions (long-term memory) and to modulation of brain functions outside HPC ("frontal lobe functions"), which are mainly subserved by PFC, via the HPC-PFC pathway. Our findings suggest that orchestration of prefrontal D-1 receptors and hippocampal D-2 receptors might be necessary for human executive function including working memory.

    DOI: 10.1523/JNEUROSCI.3446-08.2008

    Web of Science

    PubMed

    researchmap

  • Quantitative Analysis of NK1 Receptor in the Human Brain Using PET with F-18-FE-SPA-RQ 査読

    Masaki Okumura, Ryosuke Arakawa, Hiroshi Ito, Chie Seki, Hidehiko Takahashi, Harumasa Takano, Eisuke Haneda, Ryuji Nakao, Hidenori Suzuki, Kazutoshi Suzuki, Yoshiro Okubo, Tetsuya Suhara

    JOURNAL OF NUCLEAR MEDICINE   49 ( 11 )   1749 - 1755   2008年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    F-18-fluoroethyl-SPA-RQ (F-18-FE-SPA-RQ) was recently developed as a radioligand for the measurement of neurokinin 1 (NK1) receptor with PET. In this study, we used F-18-FE-SPA-RQ with PET to visualize and quantify NK1 receptor in the human brain. Methods: PET scans were performed on 7 healthy men after intravenous injection of F-18-FE-SPA-RQ. Binding potential (BPNp) was calculated by the indirect kinetic, simplified reference tissue model (SRTM), and ratio methods. The indirect kinetic method was used as the gold standard method and was compared with the SRTM method, with scan times of 180, 270, and 330 min, and with the ratio method, with time integration intervals of 120-180, 210-270, and 300-330 min. The cerebellum was used as the reference brain region. Results: Regional radioactivity was highest in the caudate head and putamen; mid level in the parahippocampus, cerebral cortex, and thalamus; and lowest in the cerebellum. BPND values by the indirect kinetic method were 3.15 +/- 0.36, 3.11 +/- 0.66, 1.17 +/- 0.25, and 0.46 +/- 0.14 in the caudate, putamen, parahippocampal region, and thalamus, respectively. For cerebral cortical regions, BPNp values by the indirect kinetic method were 0.94 +/- 0.23, 0.82 +/- 0.15, 0.76 +/- 0.15, and 0.69 +/- 0.16 in the occipital, temporal, frontal, and anterior cingulate cortices, respectively. BPNp values by the SRTM and ratio methods were in good agreement with those by the indirect kinetic method (r = 0.94-0.98). Conclusion: The regional distribution of F-18-FE-SPA-RQ was in agreement with previous PET studies and postmortem studies of NK1 receptor in the human brain. The ratio method will be useful for clinical research of psychiatric disorders, for the estimation of NK1 receptor without arterial blood sampling and long dynamic PET.

    DOI: 10.2967/jnumed.108.054353

    Web of Science

    PubMed

    researchmap

  • Error analysis for PET measurement of dopamine D(2) receptor occupancy by antipsychotics with [(11)C]raclopride and [(11)C]FLB 457 査読

    Yoko Ikoma, Hiroshi Ito, Ryosuke Arakawa, Masaki Okumura, Chie Seki, Miho Shidahara, Hidehiko Takahashi, Yuichi Kimura, Iwao Kanno, Tetsuya Suhara

    NEUROIMAGE   42 ( 4 )   1285 - 1294   2008年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Dopamine D(2) receptor occupancy by antipsychotic drugs has been measured with positron emission tomography (PET) by comparing the binding potential (BP) values before and after drug administration. This occupancy has been found to be related to clinical effects and side effects. in this study, we evaluated the in simulation and human studies of [(11)C]raclopride and for the high affinity ligand [(11)C]FLB 457. Time-activity curves of [(11)C]raclopride and [(11)C]FLB 457 were simulated, and the reliability of BP estimated by a simplified reference tissue model and the calculated Occupancy were investigated for various noise levels, BP values, and scan durations. Then, in the human PET study with and without antipsychotics, the uncertainty of BP and occupancy estimates and the scan duration required for a reliable estimation were investigated by a bootstrap approach. Reliable and unbiased estimates of [(11)C]raclopride BP(ND) could be obtained with recording as short as 32 min, with the relative standard deviation (SD) of the striatal occupancy remaining less than 10%. Conversely, in [(11)C]FLB 457 Studies, the mean value increased and SD of the temporal cortex and thalamus exceeded 10% when the scan duration was shorter than 60 min. These results demonstrated that dopamine D(2) receptor occupancy by antipsychotics can be estimated precisely with an optimal scan duration with [(11)C]raclopride and [(11)C]FLB 457. (C) 2008 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.neuroimage.2008.05.056

    Web of Science

    PubMed

    researchmap

  • (S,S)-[18F]FMeNER-D2による脳内ノルエピネフリントランスポーターの定量 査読

    荒川 亮介, 奥村 正紀, 伊藤 浩, 高橋 英彦, 高野 晴成, 関 千江, 大久保 善朗, 須原 哲也

    核医学   45 ( 3 )   S227 - S227   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • [18F]FE-SPA-RQによる脳内NK1受容体の定量 査読

    奥村 正紀, 荒川 亮介, 伊藤 浩, 高橋 英彦, 高野 晴成, 関 千江, 大久保 善朗, 須原 哲也

    核医学   45 ( 3 )   S228 - S228   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-F-18-FMeNER-D-2 査読

    Ryosuke Arakawa, Masaki Okurnura, Hiroshi Ito, Chie Seki, Hidehiko Takahashi, Harumasa Takano, Ryuji Nakao, Kazutoshi Suzuki, Yoshiro Okubo, Christer Halldin, Tetsuya Suhara

    JOURNAL OF NUCLEAR MEDICINE   49 ( 8 )   1270 - 1276   2008年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SOC NUCLEAR MEDICINE INC  

    (S,S)-F-18-FMeNER-D-2 was recently developed as a radioligand for the measurement of norepinephrine transporter imaging with PET. In this study, a norepinephrine transporter was visualized in the human brain using this radioligand with PET and quantified by several methods. Methods: PET scans were performed on 10 healthy men after intravenous injection of (S,S)-(FFMeNER)-F-18-D-2. Binding potential relative to nondisplaceable binding (BPND) was quantified by the indirect kinetic, simplified reference-tissue model (SRTM), multilinear reference-tissue model (MRTM), and ratio methods. The indirect kinetic method was used as the gold standard and was compared with the SRTM method with scan times of 240 and 180 min, the MRTM method with a scan time of 240 min, and the ratio method with a time integration interval of 120-180 min. The caudate was used as reference brain region. Results: Regional radioactivity was highest in the thalamus and lowest in the caudate during PET scanning. BPND values by the indirect kinetic method were 0.54 +/- 0.19 and 0.35 +/- 0.25 in the thalamus and locus coeruleus, respectively. BPND values found by the SRTM, MRTM, and ratio methods agreed with the values demonstrated by the indirect kinetic method (r = 0.81-0.92). Conclusion: The regional distribution of (S,S)-F-18-FMeNER-D-2 in our study agreed with that demonstrated by previous PET and postmortem studies of norepinephrine transporter in the human brain. The ratio method with a time integration interval of 120-180 min will be useful for clinical research of psychiatric disorders for estimation of norepinephrine transporter occupancy by antidepressants without requiring arterial blood sampling and dynamic PET.

    DOI: 10.2967/jnumed.108.051292

    Web of Science

    PubMed

    researchmap

  • Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D(2) receptor occupancy in patients with schizophrenia 査読

    Ryosuke Arakawa, Hiroshi Ito, Akihiro Takano, Hidehiko Takahashi, Takuya Morimoto, Takeshi Sassa, Katsuya Ohta, Motoichiro Kato, Yoshiro Okubo, Tetsuya Suhara

    PSYCHOPHARMACOLOGY   197 ( 2 )   229 - 235   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    Rationale Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects.
    Objectives In this study, we measured striatal and extrastriatal dopamine D(2) receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose.
    Materials and methods Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [(11)C]raclopride and one with [(11)C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D(2) receptor occupancy was calculated.
    Results The dopamine D(2) receptor occupancies in the striatum measured with [(11)C]raclopride and the temporal cortex measured with [(11)C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively. ED(50) values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D(2) receptor occupancy between the striatum and the temporal cortex.
    Conclusions The data from this study suggest that paliperidone ER at 6-9 mg provides an estimated level of dopamine D(2) receptor occupancy between 70-80% and that the magnitude of dopamine D(2) receptor occupancy is similar between the striatum and temporal cortex.

    DOI: 10.1007/s00213-007-1029-z

    Web of Science

    PubMed

    researchmap

  • GABA(A)/Benzodiazepine receptor binding in patients with schizophrenia using [C-11]Ro15-4513, a radioligand with relatively high affinity for alpha 5 subunit 査読

    Yoshiyuki Asai, Akihiro Takano, Hiroshi Ito, Yoshiro Okubo, Masato Matsuura, Akihiko Otsuka, Hidehiko Takahashi, Tomomichi Ando, Shigeo Ito, Ryosuke Arakawa, Kunihiko Asai, Tetsuya Suhara

    SCHIZOPHRENIA RESEARCH   99 ( 1-3 )   333 - 340   2008年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE BV  

    Dysfunction of the GABA system is considered to play a role in the pathology of schizophrenia. Individual subunits of GABA(A)/Benzodiazepine (BZ) receptor complex have been revealed to have different functional properties. alpha 5 subunit was reported to be related to learning and memory. Changes of a5 subunit in schizophrenia were reported in postmortem studies, but the results were inconsistent. In this study, we examined GABA(A)/BZ receptor using [C-11]Rol5-4513, which has relatively high affinity for (alpha 5 subunit, and its relation to clinical symptoms in patients with schizophrenia. [C-11]Rol5-4513 bindings of I I patients with schizophrenia (6 drug-naive and 5 drug-free) were compared with those of 12 age-matched healthy control subjects using positron emission tomography. Symptoms were assessed using the Positive and Negative Syndrome Scale. [C-11]Rol5-4513 binding was quantified by binding potential (BP) obtained by the reference tissue model. [C-11] Ro15-4513 binding in the prefrontal cortex and hippocampus was negatively correlated with negative symptom scores in patients with schizophrenia, although there was no significant difference in BP between patients and controls. GABAA/BZ receptor including alpha 5 subunit in the prefrontal cortex and hippocampus might be involved in the pathophysiology of negative symptoms of schizophrenia. (C) 2007 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.schres.2007.10.014

    Web of Science

    PubMed

    researchmap

  • Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography 査読

    Hiroshi Ito, Hidehiko Takahashi, Ryosuke Arakawa, Harumasa Takano, Tetsuya Suhara

    NEUROIMAGE   39 ( 2 )   555 - 565   2008年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    The central dopaminergic system is of interest in the pathophysiology of schizophrenia and other neuropsychiatric disorders. Both pre- and postsynaptic dopaminergic functions can be estimated by positron emission tomography (PET) with different radiotracers. However, an integrated database of both pre- and postsynaptic dopaminergic neurotransmission components including receptors, transporter, and endogenous neurotransmitter synthesis has not yet been reported. In the present study, we constructed a normal database for the pre- and postsynaptic dopaminergic functions in the living human brain using PET. To measure striatal and extrastriatal dopamine D-1 and D-2 receptor bindings, dopamine transporter binding, and endogenous dopamine synthesis rate, PET scans were performed on healthy men after intravenous injection of [C-11]SCH23390, [C-11]raclopride, [C-11]FLB457, [C-11]PE21, or L-[beta-C-11]DOPA. All PET images were anatomically standardized using SPM2, and a database was built for each radiotracer. Gray matter images were segmented and extracted from all anatomically standardized magnetic resonance images using SPM2, and they were used for partial volume correction. These databases allow the comparison of regional distributions of striatal and extrastriatal dopamine D, and D2 receptors, dopamine transporter, and endogenous dopamine synthesis capability. These distributions were in good agreement with those from human postmortem studies. This database can be used in various researches to understand the physiology of dopaminergic functions in the living human brain. This database could also be used to investigate regional abnormalities of dopaminergic neurotransmission in neuropsychiatric disorders. (C) 2007 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.neuroimage.2007.09.011

    Web of Science

    PubMed

    researchmap

  • 脳ドーパミン作動性神経伝達機能の正常データベース構築 査読

    伊藤 浩, 高橋 英彦, 荒川 亮介, 高野 晴成, 須原 哲也

    核医学   44 ( 3 )   259 - 259   2007年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Measurement of glycine binding site of N-methyl-D-asparate receptors in living human brain using 4-acetoxy derivative of L-703,717, 4-Acetoxy-7-chloro-3-[3-(4-[C-11] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography 査読

    Ryohei Matsumoto, Terushi Haradahira, Hiroshi Ito, Yota Fujimura, Chie Seki, Yoko Ikoma, Jun Maeda, Ryosuke Arakawa, Akihiro Takano, Hidehiko Takahashi, Makoto Higuchi, Kazutoshi Suzuki, Kenji Fukui, Tetsuya Suhara

    SYNAPSE   61 ( 10 )   795 - 800   2007年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-LISS  

    N-methyl-D-aspartate (NMDA) receptors are of major interest in brain functions and neuropsychiatric disorders. However, at present there are few suitable radioligands for in vivo imaging of NMDA receptors. 7-Choloro-4-hydroxy-3[3-(4-methoxybenzyl) phenyl]-2(1H)-quinolone (L-703,717) is one of the potent ligands for the glycine-binding site of NMDA receptors. 4-Acetoxy derivative of L-703,717 (AcL703) is a candidate, as a positron emission tomography (PET) ligand for NMDA receptors, because of its better permeability at the blood-brain barrier compared with L-703,717. After intravenous injection of 624-851 MBq of [C-11]AcL703, dynamic PET scan was performed on six healthy males for 90 min. Regions-of-interest were located on the cerebral cortices, cerebellar cortex, and cerebral white matter. The binding potential (BP) was calculated from the ratio of the area under the curve (AUC) of radioactivities from 40 to 90 min in the target region to that in white matter. Regional radioactivities reached close to equilibrium in all regions after about 40 min postinjection. Regional brain uptake of [C-11]AcL703 at 40 min after injection was 0.00028-0.00065% of the injected dose/milliliter. Radioactivity concentration of [C-11]AcL703 was highest in the cerebellar cortex and lowest in white matter. AUC in the cerebellar cortex was higher than those of cerebral cortices, thalamus, striatum, and white matter. BP in the cerebellar cortex was twofold higher than in the cerebral cortices (cerebellar cortex: BP = 2.20 +/- 0.72; cerebral cortices: BP = 1.05 +/- 0.45). Despite the low brain uptake of [C-11]AcL703, regional distributions were in good agreement with our previous studies of rodents. This indicates the possibility of in vivo evaluation of NMDA receptors using PET with [C-11]AcL703 in living human brain. Synapse 61:795-800, 2007. (C) 2007 Wiley-Liss, Inc.

    DOI: 10.1002/syn.20415

    Web of Science

    PubMed

    researchmap

  • Relationship between neuroticism personality trait and serotonin transporter binding 査読

    Akihiro Takano, Ryosuke Arakawa, Mika Hayashi, Hidehiko Takahashi, Hiroshi Ito, Tetsuya Suhara

    BIOLOGICAL PSYCHIATRY   62 ( 6 )   588 - 592   2007年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Background: Personality trait is thought to be one of the important factors for vulnerability to depression. The relation between serotonin transporter (5-HTT) polymorphism and anxiety-related personality has been investigated in genetic research. In this study, we investigated the relation between in vivo regional 5-HTT binding in the brain and personality inventory measures in normal male volunteers.
    Methods: Thirty-one healthy male volunteers underwent positron emission tomography scans with C-11-labeled 3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl) benzonitrile ([C-11]DASB) to measure 5-HTT and completed revised NEO Personality Inventory. Correlation of [C-11]DASB binding potentials (BP) with personality inventory measures was calculated using region-of-interest analysis and statistical parametric mapping based on the BP images.
    Results: Neuroticism was positively correlated with 5-HTT binding in the thalamus (p = .004). No significant correlation was observed in any other brain region. Within the neuroticism dimension, the facet of depression was positively correlated with 5-HTT binding in the thalamus (P = .001).
    Conclusions: Subjects with higher thalamic 5-HTT binding are more likely to express higher levels of neuroticism and depressive feeling. Serotonin transporter binding in the thalamus might be a marker of vulnerability to depression.

    DOI: 10.1016/j.biopsych.2006.11.007

    Web of Science

    PubMed

    researchmap

  • Effects of the reference tissue setting on the parametric image of C-11-WAY 100635 査読

    Akihiro Takano, Hiroshi Ito, Ryosuke Arakawa, Tomoyuki Saijo, Tetsuya Suhara

    NUCLEAR MEDICINE COMMUNICATIONS   28 ( 3 )   193 - 198   2007年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:LIPPINCOTT WILLIAMS & WILKINS  

    Objectives C-11-WAY 100635 has been used widely in the PET research field to measure 5-HT1A receptors in the living human brain. Reference tissue model analysis, in which the cerebellum was used as the reference tissue, was employed in clinical studies. However, the reported binding potentials varied greatly among the reports. In this study, regions of interest (ROIs) of the cerebellum for C-11-WAY 100635 were determined in five different approaches for six healthy male volunteers, and the effects on binding potential parametric images were compared.
    Methods First, ROIs on the cerebellar cortex were decided based on information from magnetic resonance imaging (MRI), and then divided into upper and lower parts. They were then refined according to coregistered positron emission tomography (PET) image information, generating upper-refined and lower-refined parts. In a different approach, circular ROIs were decided upon, based on the PET images, and the areas under the curve (AUCs) of five ROIs were compared. Parametric images of binding potentials were calculated with the five ROIs as the reference, and compared with each other.
    Results The AUCs of the lower-refined parts were the lowest among the first four ROIs. The ratio of the AUCs between the upper part and lower-refined part was 1.54 +/- 0.17, that between the upper-refined part and lower-refined part was 1.27 +/- 0.21, that between the lower part and lower-refined part was 1.04 +/- 0.02, and that between the circular ROIs and lower-refined part was 1.01 +/- 0.04. The differences in AUCs among the five cerebellar parts led to significant differences in the binding potential parametric images.
    Conclusion The binding potential parametric images of C-11-WAY100635 could vary significantly according to the different methods of establishing ROIs, using the cerebellum as the reference tissue, because radioactivity in the cerebellum for C-11-WAY100635 is very low.

    DOI: 10.1097/MNM.0b013e328013ebec

    Web of Science

    PubMed

    researchmap

  • 過鎮静

    荒川 亮介, 大久保 善朗

    臨床精神医学   増刊   69 - 72   2007年

     詳細を見る

    記述言語:日本語  

    researchmap

  • Striatal and extrastriatal dopamine D2 receptor occupancy by paliperidone extended-release tablets: A PET study 査読

    R. Arakawa, H. Ito, A. Takano, H. Takahashi, T. Morimoto, T. Sassa, K. Ota, M. Kato, Y. Okubo, T. Suhara

    Journal of Cerebral Blood Flow and Metabolism   27 ( SUPPL. 1 )   BP15-03U   2007年

     詳細を見る

    記述言語:英語  

    researchmap

  • Serotonin transpoter binding in patients with obsessive compulsive disorders: A PET with [11C] DASB 査読

    R. Matsumoto, H. Ito, Y. Fujimura, Y. Ikoma, C. Seki, J. Kosaka, R. Arakawa, T. Ando, A. Takano, H. Takahashi, K. Fukui, T. Suhara

    Journal of Cerebral Blood Flow and Metabolism   27 ( SUPPL. 1 )   BP29-05U   2007年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)  

    Background and aims: Obsessive compulsive disorder (OCD) is psychiatric disorder characterized by recurrent obsessions and compulsions. Based on the selective efficacy of serotonin reuptake inhibitors (SRIs) and comorbid depression that is often observed in OCD, the serotonergic system including serotonin transporter (SERT) has been of interest in pathophysiology of OCD. Previous study using positron emission tomography (PET) with a radiotracer [11C]McN5642 for SERT failed to changes in density of SERT in OCD patients. The aim of the present study is to investigate SERT density using [11C]DASB which shows high selectivity and affinity to SERT as compared with [11C]McN5642. Methods: Ten patients with OCD, free of psychiatric medication and comorbid depression, and 18 gender and age-matched healthy subjects participate in this study. OCD was diagnosed according to the DSM-IV. OCD severity was assessed by Yale?Brown Obsessive?Compulsive Scale (Y-BOCS, scale range: 0?40). After intravenous infusion of [11C]DASB, a dynamic PET scanning was performed for 90 min. Regions-of-interest were defined on the frontal cortex, thalamus, striatum and midbrain on the coregistered magnetic resonance images. The binding potential (BP) of [11C]DASB was calculated using a two-parameter multilinear reference tissue model (MRTM2) developed by Ichise et at al. Results: As shown that Y-BOCS score was 22±7.6 (range: 7-32), the degree of severity in the present subjects varied relatively widely. BP values for OCD patients were 0.17±0.05, 1.48±0.10, 1.20±0.09, and 1.35±0.28, and values for healthy controls were 0.22±0.10, 1.60±0.24, 1.53±0.33, and 1.24±0.20 in the frontal cortex, thalamus, striatum and midbrain, respectively. No significant group differences were observed in BP of [11C]DASB in any of brain regions. No significant correlations were observed between severity of OCD and BP. Conclusions: Although SERT has been of interest in pathophysiology of OCD, no significant differences were observed in SERT density between OCD and healthy controls, same as the previous study using [11C]McN5642. OCD without comorbid depression may not be associated in only serotonergic system, but also other neurotransmission systems.

    Scopus

    researchmap

  • Normal database of the serotonergic neurotransmission system in living human brain as measured by PET 査読

    H. Takano, H. Ito, H. Takahashi, R. Arakawa, R. Matsumoto, T. Suhara

    Journal of Cerebral Blood Flow and Metabolism   27 ( SUPPL. 1 )   PP05-03M   2007年

     詳細を見る

    記述言語:英語  

    researchmap

  • Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. 査読

    Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, Fukumura T, Nakao R, Suzuki K, Suhara T

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   47 ( 9 )   1531 - 1537   2006年9月

     詳細を見る

    記述言語:英語  

    PubMed

    researchmap

  • PETを用いた向精神薬の至適服薬量の決定

    荒川亮介, 須原哲也

    Isotope News   627 ( 7 )   2 - 5   2006年

     詳細を見る

    記述言語:日本語  

    researchmap

  • 抗精神病薬による維持療法時のドーパミンD2受容体占有量の検討

    荒川亮介, 大久保善朗, 一宮哲也, 舘野周, 西條朋行, 伊藤敬雄, 高野晶寛, 安野史彦, 須原哲也

    精神薬療研究年報   37   2005年

     詳細を見る

    記述言語:日本語  

    researchmap

  • テーラーメード治療に向けての脳機能画像と遺伝多型での評価

    荒川亮介, 伊藤浩, 高野晶寛, 森本卓也, 高橋英彦, 須原哲也

    精神科   7 ( 5 )   413 - 417   2005年

     詳細を見る

    記述言語:日本語  

    researchmap

  • 催眠施行中における脳波変化:催眠感受性の異なる2被験者のフラクタル次元解析:第2報

    荒川亮介, 森隆夫, 竹澤健司, 鈴木博子, 木村真人, 大久保善朗

    催眠と科学   19 ( 1 )   47 - 49   2004年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本催眠学会  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2006191975

  • 催眠施行中における脳波のフラクタル次元解析:催眠感受性の異なる2被験者について

    荒川亮介, 木村真人, 森隆夫, 竹澤健司, 葉田道雄, 遠藤俊吉

    催眠と科学   18 ( 1 )   45 - 48   2003年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本催眠学会  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2006203730

  • 形成外科領域における,カラーチャートを用いたデジタルカメラの比較検討

    小川令, 荒川亮介, 百束比古, 青木律, 三橋清

    形成外科   44 ( 8 )   809 - 814   2001年

     詳細を見る

    記述言語:日本語   出版者・発行元:克誠堂出版(株)  

    10万円前後で購入できる一般向けオートマチックのデジタルカメラ230万画素クラスのもの9種及び,300万画素クラスのもの9種と,フィルムカメラを対象に,色調の再現性を検討した.3原色各々について,撮影した写真と基準のカラーチャートとのずれを数値で表現したところ,デジタルカメラでは機種により再現性に差があったが,フィルムカメラより優れたものはなかった.又,230万画素クラスのものと300万画素クラスのものでは,明確な違いは認めなかった

    researchmap

▼全件表示

MISC

  • セルトラリンのドパミン神経伝達への作用に関するPET研究

    金禹瑣, 舘野周, 池田裕美子, 坂寄健, 荒川亮介, 荒川亮介, 鈴木秀典, 大久保善朗

    日本生物学的精神医学会(Web)   38th   168 (WEB ONLY)   2016年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ブプロピオンのドパミン神経伝達への作用に関するPET研究

    金 禹瑣, 舘野 周, 池田 裕美子, 坂寄 健, 荒川 亮介, 鈴木 秀典, 大久保 善朗

    日本生物学的精神医学会・日本神経精神薬理学会合同年会プログラム・抄録集   37回・45回   183 - 183   2015年9月

     詳細を見る

    記述言語:日本語  

    researchmap

  • セレギリンのドパミン情報伝達系への作用に関するPET研究

    金 禹瑣, 舘野 周, 池田 裕美子, 坂寄 健, 荒川 亮介, 鈴木 秀典, 大久保 善朗

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   24回・44回   195 - 195   2014年11月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 精神医学のフロンティア 統合失調症の脳形態変化における閉経の影響について

    福田 一, 伊藤 逸生, 舘野 周

    精神神経学雑誌   115 ( 12 )   1178 - 1185   2013年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本精神神経学会  

    統合失調症の脳形態変化における閉経の影響について、患者群を閉経患者と非閉経患者の2群に分けMRIを用いて調査した。最終月経からMRI撮像までの期間が12ヵ月以上である統合失調症女性患者20名と同時期が12ヵ月未満であり閉経患者群と年齢を一致させた統合失調症女性患者20名(平均41.8±9.0歳)を対象とした。分析の結果、非閉経患者群と比較し、閉経患者群において左中前頭回の灰白質に有意な体積減少を認めた。一方、非閉経患者群が閉経患者群と比較して有意に体積減少している部位は認められなかった。閉経患者20名において、閉経後経過年数と脳体積の相関を調べた結果、右上前頭回の灰白質体積と閉経後経過年数に負の相関が認められた。健常者が閉経する平均年齢は50から52歳の間であるとされるが、今回の閉経患者群においては、若年期に最終月経がきており、原因の一つに抗精神薬の副作用であることが考えられた。

    CiNii Books

    researchmap

  • [11]DASBを用いたトラマドールのセロトニントランスポーターの占有率についての陽電子放射断層撮影(PET)研究 鎮痛効果の作用機序と抗うつ作用の可能性

    小川 耕平, 舘野 周, 荒川 亮介, 坂寄 健, 池田 裕美子, 鈴木 秀典, 大久保 善朗

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   23回・43回   182 - 182   2013年10月

     詳細を見る

    記述言語:日本語  

    researchmap

  • 東日本大震災と新潟県中越地震におけるこころのケアチームリーダーの活動の比較

    小見 めぐみ, 渡 路子, 荒川 亮介, 金 吉晴

    国立精神・神経医療研究センター精神保健研究所年報   ( 26 )   235 - 235   2013年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(国研)国立精神・神経医療研究センター精神保健研究所  

    researchmap

  • 東日本大震災こころのケアチームの全国の活動実績に基づいた災害時こころの情報支援センターの活動

    渡 路子, 小見 めぐみ, 荒川 亮介, 金 吉晴

    国立精神・神経医療研究センター精神保健研究所年報   ( 26 )   235 - 235   2013年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(国研)国立精神・神経医療研究センター精神保健研究所  

    researchmap

  • モダフィニルのPET神経画像評価

    金 禹瑣, 舘野 周, 坂寄 健, 荒川 亮介, 大久保 善朗

    精神神経学雑誌   ( 2013特別 )   S - 684   2013年5月

     詳細を見る

    記述言語:日本語  

    researchmap

  • Norepinephrine in the brain is associated with aversion to financial loss

    H. Takahashi, S. Fujie, C. Camerer, R. Arakawa, H. Takano, F. Kodaka, H. Matsui, T. Ideno, S. Okubo, K. Takemura, M. Yamada, Y. Eguchi, T. Murai, Y. Okubo, M. Kato, H. Ito, T. Suhara

    MOLECULAR PSYCHIATRY   18 ( 1 )   3 - 4   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:速報,短報,研究ノート等(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    DOI: 10.1038/mp.2012.7

    Web of Science

    researchmap

  • Regional distribution of dopamine D-2 receptor occupancy by aripiprazole: a PET study using [C-11]raclopride and [C-11]FLB457

    Keisuke Takahata, Hiroshi Ito, Harumasa Takano, Kodaka Fumitoshi, Ryosuke Arakawa, Tetsuya Suhara

    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM   32   S43 - S44   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Effects of the partial agonist antipsychotic on dopamine synthesis capacity in human brain measured by PET with [C-11]DOPA

    Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Keisuke Takahata, Fumitoshi Kodaka, Hidehiko Takahashi, Tetsuya Suhara

    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM   32   S42 - S43   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • 線条体の機能的分類におけるドーパミンD2受容体密度と性格特性の関連についての検討

    江口洋子, 高野晴成, 伊藤浩, 荒川亮介, 小高文聰, 高橋英彦, 須原哲也, 松田博史

    核医学   48 ( 2 )   154   2011年5月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • [11C]MNPAを用いた脳内ドーパミンD2受容体結合能測定の再現性

    藤江沙織, 伊藤浩, 高野晴成, 荒川亮介, 小高文聰, 佐々木健至, 高橋英彦, 須原哲也

    核医学   47 ( 3 )   S214   2010年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • [11C]MNPAを用いたドーパミンD2受容体占有率測定における誤差解析

    志田原美保, 伊藤浩, 大塚達以, 生駒洋子, 荒川亮介, 小高文聰, 関千江, 高野晴成, 高橋英彦, 田村元, 須原哲也

    核医学   47 ( 3 )   S215   2010年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ドーパミン作動性神経系における前シナプス機能と後シナプス機能の関係

    伊藤浩, 高橋英彦, 高野晴成, 荒川亮介, 小高文聰, 須原哲也

    核医学   47 ( 3 )   S214   2010年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • [18F]FE‐PE21による脳内ドーパミントランスポーターの定量

    佐々木健至, 荒川亮介, 高野晴成, 関千江, 小高文聰, 藤江沙織, 伊藤浩, 須原哲也

    核医学   47 ( 3 )   S215   2010年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ドーパミンD2/3受容体のhighおよびlow affinity stateの脳内分布

    小高文聰, 伊藤浩, 高野晴成, 高橋英彦, 荒川亮介, 藤江沙織, 中山和彦, 須原哲也

    核医学   47 ( 3 )   S214   2010年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 線条体ドーパミンD2受容体と性格特性との関連

    江口 洋子, 高野 晴成, 伊藤 浩, 荒川 亮介, 小高 文聰, 高橋 英彦, 松田 博史, 須原 哲也

    核医学   47 ( 3 )   368 - 368   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本核医学会  

    researchmap

  • Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride

    Fumitoshi Kodaka, Hiroshi Ito, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Saori Fujie, Takeshi Sasaki, Kazuhiko Nakayama, Christer Halldin, Lars Farde, Tetsuya Suhara

    NEUROIMAGE   52   S95 - S95   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    DOI: 10.1016/j.neuroimage.2010.04.076

    Web of Science

    researchmap

  • Relation between pre- and postsynaptic dopaminergic functions measured by PET: Implication of dopaminergic tone

    Hiroshi Ito, Hidehiko Takahashi, Harumasa Takano, Ryosuke Arakawa, Fumitoshi Kodaka, Tetsuya Suhara

    NEUROIMAGE   52   S101 - S101   2010年8月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    DOI: 10.1016/j.neuroimage.2010.04.081

    Web of Science

    researchmap

  • Dose-finding study of blonanserin based on striatal and extrastriatal dopamine D-2 receptor occupancy in patients with schizophrenia

    A. Tateno, R. Arakawa, M. Okumura, H. Fukuta, K. Ishihara, S. Kumita, Y. Okubo

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   13   107 - 107   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    Web of Science

    researchmap

  • 抗精神病薬による脳内ドーパミン生成能変化の検討

    伊藤浩, 高野晴成, 高橋英彦, 荒川亮介, 小高文聰, 須原哲也

    核医学   46 ( 3 )   S253   2009年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 健常人の個人内の脳内セロトニントランスポーターとセロトニン1A受容体の関連‐PETによる検討

    高野晴成, 伊藤浩, 荒川亮介, 高橋英彦, 三好美智恵, 小高文聰, 須原哲也

    核医学   46 ( 3 )   S255   2009年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ドーパミンD2受容体アゴニストリガンド[11C]MNPAを用いたリスペリドンによる受容体占有率の測定

    小高文聰, 伊藤浩, 荒川亮介, 高野晴成, 高橋英彦, 須原哲也

    核医学   46 ( 3 )   S253   2009年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ドーパミンD1およびD2受容体の扁桃体活動への関わり

    高橋英彦, 高野晴成, 小高文聰, 荒川亮介, 三好美智恵, 関根瑞保, 伊藤浩, 須原哲也

    核医学   46 ( 3 )   S253   2009年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ドーパミンD2受容体アゴニストリガンド[11C]MNPAを用いたアリピプラゾールの受容体占有率測定

    荒川亮介, 伊藤浩, 小高文聰, 関根瑞保, 高橋英彦, 高野晴成, 須原哲也

    核医学   46 ( 3 )   S254   2009年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 抗精神病薬投与時のドーパミンD2レセプター占有率の脳内局所差に関する研究

    伊藤浩, 須原哲也, 高橋英彦, 高野晴成, 荒川亮介, 奥村正紀, 大塚達以, 小高文聰, 志田原美保

    精神薬療研究年報   ( 41 )   17 - 18   2009年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 統合失調症の治療--分子イメージングで探る合理的薬物療法 (シンポジウム 統合失調症の脳科学)

    須原 哲也, 荒川 亮介

    精神医学   51 ( 2 )   171 - 176   2009年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学書院  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2009105176

  • 抗精神病薬投与時ドーパミンD2レセプター占有率の脳内局所差の検討

    伊藤浩, 荒川亮介, 高橋英彦, 高野晴成, 奥村正紀, 大塚達以, 小高文聰, 志田原美保, 須原哲也

    核医学   45 ( 3 )   S229   2008年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ヒト脳におけるドーパミンD2受容体アゴニスト放射性リガンド[11C]MNPAの動態解析

    大塚達以, 伊藤浩, 高橋英彦, 高野晴成, 荒川亮介, 奥村正紀, 小高文聰, 三好美智恵, 関千江, 平安良雄, 須原哲也

    核医学   45 ( 3 )   S227   2008年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 異なるPET装置でのドーパミンD2受容体結合能の比較

    小高文聰, 伊藤浩, 高橋英彦, 高野晴成, 荒川亮介, 奥村正紀, 大塚達以, 三好美智恵, 関根瑞穂, 志田原美保, 須原哲也

    核医学   45 ( 3 )   S237   2008年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • PETによるヒト脳内セロトニン神経系の正常データベースの作成

    高野晴成, 伊藤浩, 高橋英彦, 荒川亮介, 奥村正紀, 小高文聰, 大塚達衣, 須原哲也

    核医学   45 ( 3 )   S197   2008年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 精神症状 過鎮静 (必須! 向精神薬の副作用と対策--安全な薬物療法のために) -- (臓器別副作用)

    荒川 亮介, 大久保 善朗

    臨床精神医学   36   69 - 72   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:アークメディア  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2008155447

  • Serotonin transporter occupancy of serotonin and norepinephrine reuptake inhibitor, milnacipran: A pet study with [C-11]DASB

    T. Ichimiya, Y. Okubo, R. Arakawa, M. Okumura, A. Takano, H. Ito, T. Suhara

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY   9   S110 - S110   2006年7月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:CAMBRIDGE UNIV PRESS  

    Web of Science

    researchmap

  • Evaluation of reference tissue models for the quantitative analysis of [11C]PE2I binding in human brain

    Chie Seki, H. Ito, T. Ichimiya, R. Arakawa, Y. Ikoma, J. Maeda, A. Takano, H. Takahashi, K. Suzuki, T. Suhara

    NEUROIMAGE   31   T19 - T19   2006年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    DOI: 10.1016/j.neuroimage.2006.04.010

    Web of Science

    researchmap

  • 口腔内疼痛性障害の薬物療法および脳血流評価

    荒川 亮介, 舘野 周, 水村 直, 岡田 智雄, 石井 隆資, 大津 光寛, 長谷川 功, 苅部 洋行, 大久保 善朗

    日本歯科心身医学会雑誌   19 ( 1〜2 )   112 - 112   2004年12月

     詳細を見る

    記述言語:日本語  

    researchmap

▼全件表示

講演・口頭発表等

  • PETを用いたSNRI・milnacipranのセロトニントランスポーター占有率の測定

    一宮哲哉, 荒川亮介, 奥村正紀, 舘野周, 伊藤敬雄, 齊藤卓弥, 高野晶寛, 伊藤浩, 須原哲也, 大久保善朗

    第3回うつ病学会  2006年7月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • ペロスピロンによるドーパミンD2受容体占有率の経時変化

    荒川亮介, 伊藤浩, 奥村正紀, 大久保善朗, 須原哲也

    第28回日本生物学的精神医学会  2006年9月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • ペロスピロンによる脳内ドーパミンD2受容体占有率の経時的変化

    荒川亮介

    AAPシンポジウム2008  2008年2月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • Quantitative analysis of norepinephrine transporter binding in human brain using PET with (S,S)-[18F]FMeNER-D2

    Arakawa R

    Neuroreceptor Mapping 2008  2008年7月 

     詳細を見る

    記述言語:英語  

    researchmap

  • 抗精神病薬による下垂体ドーパミンD2受容体阻害作用と高プロラクチン血症との関係

    荒川 亮介, 伊藤 浩, 奥村 正紀, 大久保 善朗, 須原 哲也

    47回日本核医学会学術総会  2007年11月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 抗精神病薬による下垂体ドーパミンD2 受容体占有率についての検討:高プロラクチン血症との関係

    荒川 亮介, 伊藤 浩, 奥村 正紀, 大久保 善朗, 須原 哲也

    第28回日本生物学的精神医学会  2007年11月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 分子イメージングによる精神疾患の病態研究および薬効評価

    荒川亮介

    第116回日本薬理学会関東部会  2007年6月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • スルピリド内服時の下垂体ドーパミンD2受容体占有率の測定

    奥村 正紀, 伊藤 浩, 荒川 亮介, 大久保 善朗, 須原 哲也

    第47回日本核医学会学術総会  2007年11月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 統合失調症における,探索眼球運動と脳体積との関連について

    福田一, 鈴木正泰, 伊藤逸生, 八幡憲明, 舘野周, 荒川亮介, 奥村正紀, 鈴木秀典, 松島英介, 小島卓也, 浅井邦也, 大久保善朗

    第26回日本精神科診断学会  2006年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • Striatal and extrastriatal dopamine D2 receptor occupancy by paliperidone extended-release tablets: a PET study.

    Arakawa R

    Brain 07 and Brain PET 07  2007年5月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Quantification of [11C]PBR28 using venous blood sampling and population-based input function approach as less invasive method.

    Arakawa R

    Neuroreceptor Mapping 2018  2018年7月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Quantitative evaluation of the Mediso high resolution PET/CT system LFER150 using non-human primate brain imaging.

    Arakawa R

    Annual Congress of the European-Association-of-Nuclear Medicine 2018  2018年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • A methodology study to assess binding kinetics and test-retest repeatability of the PDE4B PET radioligand [18F]PF-06445974 in healthy subjects.

    Arakawa R

    Neuroreceptor Mapping 2018  2018年7月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Target occupancy study and whole body dosimetry with a MAGL PET ligand [11C]PF-06809247 in nonhuman primates.

    Arakawa R

    Neuroreceptor Mapping 2018  2018年7月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Radiosynthesis, initial evaluation and whole-body dosimetry of a beta-secretase (BACE) PET radioligand [C-11] PF-06684511 in nonhuman primate.

    Arakawa R

    Annual Congress of the European-Association-of-Nuclear Medicine 2017  2017年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • Quantitative evaluation of the Mediso high resolution PET/CT system LFER150 using non-human primate brain imaging.

    Arakawa R

    Annual Congress of the European-Association-of-Nuclear Medicine 2018  2018年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • PETおよび[18F]FMeNER-D2を用いたうつ病患者におけるベンラファキシン徐放剤のノルエピネフリントランスポーター占有率

    荒川亮介

    第28回日本臨床精神神経薬理学会・第48回日本神経精神薬理学会 合同年会  2018年11月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • PETを用いた統合失調症における病態および薬理研究

    荒川亮介

    第34回日本生物学的精神医学会  2012年9月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • モダフィニルのPET神経画像評価

    金 禹瑣, 舘野 周, 坂寄 健, 荒川 亮介, 大久保 善朗

    日本精神神経学会(109回)  2013年5月 

     詳細を見る

    記述言語:日本語  

    開催地:福岡  

    researchmap

  • 脳神経疾患における分子イメージング

    荒川亮介

    第49回日本核医学会学術総会  2009年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • Molecular imaging of treatment for psychiatric disorder

    Arakawa R

    The 19th Annual Meeting of Japanese Society of Pharmaceutical Health care and Sciences  2009年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • セルトラリンのドパミン神経伝達への作用に関するPET研究

    金 禹瑣, 舘野 周, 池田 裕美子, 坂寄 健, 荒川 亮介, 鈴木 秀典, 大久保 善朗

    日本生物学的精神医学会(第38回)  2016年9月 

     詳細を見る

    記述言語:日本語  

    開催地:福岡  

    researchmap

  • Target occupancy of PF-06663195 measured with a beta-secretase (BACE) PET radioligand [F-18] PF-06684511 in non-human primates.

    Arakawa R

    Congress of the European-Association-of-Nuclear Medicine 2016  2016年10月 

     詳細を見る

    記述言語:英語  

    researchmap

  • セレギリンのドパミン情報伝達系への作用に関するPET研究

    金 禹瑣, 舘野 周, 池田 裕美子, 坂寄 健, 荒川 亮介, 鈴木 秀典, 大久保 善朗

    神経精神薬理学会(第44回)  2014年11月 

     詳細を見る

    記述言語:日本語  

    開催地:名古屋  

    researchmap

  • ブプロピオンのドパミン神経伝達への作用に関するPET研究

    金 禹チャン, 舘野 周, 池田 裕美子, 坂寄 健, 荒川 亮介, 鈴木 秀典, 大久保 善朗

    日本生物学的精神医学会(第37回)・日本精神神経薬理学会(第45回)  2015年9月 

     詳細を見る

    記述言語:日本語  

    開催地:東京  

    researchmap

  • PET検査を用いた向知性薬のドーピング効果評価

    金 禹瑣, 舘野 周, 坂寄 健, 荒川 亮介, 池田 裕美子, 鈴木 秀典, 大久保善朗

    Neuro2013第36回日本神経科学大会 第56回日本神経化学会大会 第23回日本神経回路学会大会 合同大会  2013年6月 

     詳細を見る

    記述言語:日本語  

    開催地:国立京都国際会館(京都府)  

    researchmap

  • 11C]DASBを用いたトラマドールのセロトニントランスポーターの占有率についての陽電子放射断層撮影(PET)研究:鎮痛効果の作用機序と抗うつ作用の可能性

    小川 耕平, 舘野 周, 荒川 亮介, 坂寄 健, 池田 裕美子, 鈴木 秀典, 大久保 善朗

    第23回日本臨床精神神経薬理学会・第43回日本神経精神薬理学会合同年会  2013年10月 

     詳細を見る

    記述言語:日本語  

    開催地:沖縄コンベンションセンター(沖縄県)  

    researchmap

  • 抗精神病薬投与時ドーパミンD2レセプター占有率の脳内局所差の検討

    伊藤 浩, 荒川 亮介, 高橋 英彦, 高野 晴成, 奥村 正紀, 大塚 達以, 小高 文聰, 志田原 美保, 須原 哲也

    日本核医学会学術総会(第48回)  2008年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • [18F]FE-SPA-RQによる脳内NK1受容体の定量

    奥村 正紀, 荒川 亮介, 伊藤 浩, 高橋 英彦, 高野 晴成, 関 千江, 大久保 善朗, 須原 哲也

    日本核医学会学術総会(第48回)  2008年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • Extrastriatal dopamine D2 receptor occupancy by olanzapine in patients with schizophrenia.

    Arakawa R

    2nd WFSBP Asia-Pacific Congress and 30th Annual Meeting of JSBP  2008年9月 

     詳細を見る

    記述言語:英語  

    researchmap

  • ドーパミンD2受容体アゴニストリガンド[11C]MNPAを用いたアリピプラゾールの受容体占有率測定

    荒川亮介

    第49回日本核医学会学術総会  2009年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 統合失調症における視床ドーパミントランスポーターの増加:[11C]PE2Iを用いたPET研究

    荒川亮介

    第4回日本分子イメージング学会学術集会  2009年5月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • INCREASE IN THALAMIC BINDING OF [11C]PE2I IN PATIENTS WITH SCHIZOPHRENIA: A POSITRON EMISSION TOMOGRAPHY STUDY OF DOPAMINE TRANSPORTER.

    Arakawa R

    Brain 09 & Brain PET 09  2009年6月 

     詳細を見る

    記述言語:英語  

    researchmap

  • PETによる精神神経疾患のトランスポーター研究

    荒川亮介

    第18回神経行動薬理若手研究者の集い  2009年3月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 統合失調症における視床ドーパミントランスポーターの増加:[11C]PE2Iを用いたPET研究

    荒川亮介

    第31回日本生物学的精神医学会  2009年4月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • (S,S)-[18F]FMeNER-D2による脳内ノルエピネフリントランスポーターの定量

    荒川 亮介, 奥村 正紀, 伊藤 浩, 高橋 英彦, 高野 晴成, 関 千江, 大久保 善朗, 須原 哲也

    日本核医学会学術総会(第48回)  2008年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • (S,S)-[18F]FMeNER-D2を用いた脳内ノルエピネフリントランスポーターの定量解析

    荒川 亮介, 奥村 正紀, 伊藤 浩, 高橋 英彦, 高野 晴成, 関 千江, 大久保 善朗, 須原 哲也

    日本臨床精神神経薬理学会(第18回)・日本神経精神薬理学会合同年会(第38回)  2008年10月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 精神科におけるブロードバンド回線を利用した遠隔医療の可能性

    小林岐, 舘野周, 荒川亮介, 西條朋行, 清田英樹, 大久保善朗

    第25回日本精神科診断学会  2005年9月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 抗うつ薬によるセロトニンおよびノルエピネフリトランスポーター占有率に関するPET研究

    一宮哲哉, 大久保善朗, 荒川亮介, 奥村正紀, 齊藤卓弥, 高野晶寛, 伊藤浩, 須原哲也

    第38回精神神経系薬物治療研究報告会  2005年12月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • PET,MRIを用いた統合失調症の研究

    八幡憲明, 高橋英彦, 伊藤逸生, 高野晶寛, 荒川亮介, 伊藤滋朗, 安野史彦, 一宮哲哉, 西條朋行, 肥田道彦, 織田健司, 松浦雅人, 須原哲也, 大久保善朗

    厚生労働省精神・神経疾患研究委託費 平成16年度研究報告会.  2004年12月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 抗精神病薬による維持療法時のドーパミンD2受容体占有量の検討

    荒川亮介, 大久保善朗, 一宮哲也, 舘野周, 西條朋行, 伊藤敬雄, 高野晶寛, 安野史彦, 須原哲也

    第37回精神神経系薬物治療研究報告会  2004年12月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 催眠施行中における脳波変化:odd-ball課題施行中のフラクタル次元解析

    荒川亮介, 木村真人, 竹澤健司, 葉田道雄, 森隆夫, 遠藤俊吉

    第18回日本催眠学会  2002年9月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 口腔内疼痛性障害の薬物療法及び脳血流評価

    荒川亮介, 舘野周, 水村直, 岡田智雄, 石井隆資, 大津光寛, 長谷川功, 苅部洋行, 大久保善朗

    第19回日本歯科心身医学会  2004年7月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 形成外科領域におけるデジタルカメラ利用法の光学的検討

    小川令, 荒川亮介, 青木律, 三橋清, 百束比古

    第43回日本形成外科学会総会・学術集会  2000年5月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 形成外科の視点から検討したデジタルカメラの選択

    小川令, 荒川亮介, 青木律, 三橋清, 百束比古

    第68回日本医科大学医学会総会  2000年9月 

     詳細を見る

    記述言語:日本語  

    researchmap

  • うつ病相に一致して性器の幻視が出現する1症例

    荒川亮介, 小泉幸子, 田川一郎, 榮兼作, 岸泰宏, 黒澤尚

    東京精神医学会 第58回学術集会  2000年2月 

     詳細を見る

    記述言語:日本語  

    researchmap

▼全件表示

受賞

  • 第46回 (2009年度)ベルツ賞1等賞「精神疾患-うつ病,統合失調症など-」

    2009年11月   ベーリンガーインゲルハイム社   「精神疾患-うつ病,統合失調症など-」

    須原 哲也, 大久保 善朗, 安野 史彦, 高野 晶寛, 高橋 英彦, 荒川 亮介, 一宮 哲哉, 伊藤 浩, 加藤 元一郎, 樋口 真人

     詳細を見る

共同研究・競争的資金等の研究課題

  • タウ蛋白PETイメージングからみた老年期うつ病の治療反応性の解明

    2020年4月 - 2023年3月

    日本医科大学  基盤研究(C)

    荒川 亮介

      詳細を見る

    資金種別:競争的資金

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    researchmap

  • タウ蛋白および5-HT1B受容体PETによるアミロイド関連うつ病の病態解明研究

    2019年4月 - 2022年3月

    日本医科大学  基盤研究(C)

    舘野 周

      詳細を見る

    資金種別:競争的資金

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    researchmap

  • PETによる向精神薬の神経シナプス前および後機能への薬理作用の画像医学的解明

    研究課題/領域番号:21591587  2009年 - 2011年

    独立行政法人放射線医学総合研究所  科学研究費助成事業  基盤研究(C)

    伊藤 浩

      詳細を見る

    資金種別:競争的資金

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    統合失調症の治療薬である抗精神病薬は後シナプスに存在するドーパミンD2レセプターに作用するが、ドーパミンD2レセプターの遮断薬である抗精神病薬のリスペリドンおよび部分作動薬である抗精神病薬のアリピプラゾールが前シナプス機能であるドーパミン生成能に与える影響を、健常人においてPETにより測定した。両抗精神病薬共に服薬前の脳内ドーパミン生成能と服薬による脳内ドーパミン生成能変化率との間に有意な負の相関をみとめ、脳内ドーパミン生成能を安定化させる作用があることが示唆された。

    researchmap

  • 抗精神病薬による下垂体ドーパミンD2受容体占有率の脳内局所差に関する研究

    2008年

    精神薬療研究助成金 

    大久保 善朗, 荒川 亮介, 伊藤 浩, 奥村 正紀, 須原 哲也

      詳細を見る

    担当区分:連携研究者  資金種別:競争的資金

    配分額:1000000円

    researchmap